<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Botulinum toxin type A versus botulinum toxin type B for cervical dystonia - Duarte, GS - 2016 | Cochrane Library</title> <meta content="Botulinum toxin type A versus botulinum toxin type B for cervical dystonia - Duarte, GS - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004314.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Botulinum toxin type A versus botulinum toxin type B for cervical dystonia - Duarte, GS - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004314.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD004314.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Botulinum toxin type A versus botulinum toxin type B for cervical dystonia" name="citation_title"/> <meta content="Gonçalo S Duarte&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Mafalda Castelão&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Filipe B Rodrigues&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Raquel E Marques&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Joaquim Ferreira" name="citation_author"/> <meta content="Cristina Sampaio" name="citation_author"/> <meta content="CHDI Foundation" name="citation_author_institution"/> <meta content="Austen P Moore" name="citation_author"/> <meta content="The Walton Centre NHS Foundation Trust" name="citation_author_institution"/> <meta content="João Costa" name="citation_author"/> <meta content="jncosta@medicina.ulisboa.pt" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD004314.pub3" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/10/26" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004314.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004314.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004314.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Botulinum Toxins, Type A [adverse effects, *therapeutic use]; Dystonia [*congenital, drug therapy]; Neuromuscular Agents [adverse effects, *therapeutic use]; Randomized Controlled Trials as Topic; Torticollis [*drug therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004314.pub3&amp;doi=10.1002/14651858.CD004314.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004314.pub3&amp;doi=10.1002/14651858.CD004314.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004314.pub3&amp;doi=10.1002/14651858.CD004314.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004314.pub3&amp;doi=10.1002/14651858.CD004314.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004314.pub3&amp;doi=10.1002/14651858.CD004314.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004314.pub3&amp;doi=10.1002/14651858.CD004314.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004314.pub3&amp;doi=10.1002/14651858.CD004314.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004314.pub3&amp;doi=10.1002/14651858.CD004314.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004314.pub3&amp;doi=10.1002/14651858.CD004314.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004314.pub3&amp;doi=10.1002/14651858.CD004314.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004314.pub3&amp;doi=10.1002/14651858.CD004314.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004314.pub3&amp;doi=10.1002/14651858.CD004314.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004314.pub3&amp;doi=10.1002/14651858.CD004314.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004314.pub3&amp;doi=10.1002/14651858.CD004314.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004314.pub3&amp;doi=10.1002/14651858.CD004314.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004314.pub3&amp;doi=10.1002/14651858.CD004314.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004314.pub3&amp;doi=10.1002/14651858.CD004314.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004314.pub3&amp;doi=10.1002/14651858.CD004314.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004314.pub3&amp;doi=10.1002/14651858.CD004314.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004314.pub3&amp;doi=10.1002/14651858.CD004314.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004314.pub3&amp;doi=10.1002/14651858.CD004314.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004314.pub3&amp;doi=10.1002/14651858.CD004314.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004314.pub3&amp;doi=10.1002/14651858.CD004314.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="zCmos3jT";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD004314\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD004314\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004314\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004314\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","pt","hr","fa","ms"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD004314.pub3",title:"Botulinum toxin type A versus botulinum toxin type B for cervical dystonia",firstPublishedDate:"Oct 26, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Movement Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=zCmos3jT&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004314.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004314.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD004314.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD004314.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004314.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD004314.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD004314.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD004314.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD004314.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD004314.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3052 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD004314.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004314.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004314.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004314.pub3/full#CD004314-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004314.pub3/full#CD004314-sec-0100"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004314.pub3/full#CD004314-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004314.pub3/full#CD004314-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004314.pub3/full#CD004314-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004314.pub3/full#CD004314-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004314.pub3/full#CD004314-sec-0069"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004314.pub3/full#CD004314-sec-0094"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004314.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004314.pub3/appendices#CD004314-sec-0105"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004314.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004314.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/table_n/CD004314StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/table_n/CD004314StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004314.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004314.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004314.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004314.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004314.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD004314.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Botulinum toxin type A versus botulinum toxin type B for cervical dystonia</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author custom-tooltip" title="These authors contributed equally to this work"><a href="/cdsr/doi/10.1002/14651858.CD004314.pub3/information#CD004314-cr-0002">Gonçalo S Duarte</a><sup>a</sup></li> <li class="author custom-tooltip" title="These authors contributed equally to this work"><a href="/cdsr/doi/10.1002/14651858.CD004314.pub3/information#CD004314-cr-0003">Mafalda Castelão</a><sup>a</sup></li> <li class="author custom-tooltip" title="These authors contributed equally to this work"><a href="/cdsr/doi/10.1002/14651858.CD004314.pub3/information#CD004314-cr-0004">Filipe B Rodrigues</a><sup>a</sup></li> <li class="author custom-tooltip" title="These authors contributed equally to this work"><a href="/cdsr/doi/10.1002/14651858.CD004314.pub3/information#CD004314-cr-0005">Raquel E Marques</a><sup>a</sup></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004314.pub3/information#CD004314-cr-0006">Joaquim Ferreira</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004314.pub3/information#CD004314-cr-0007">Cristina Sampaio</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004314.pub3/information#CD004314-cr-0008">Austen P Moore</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004314.pub3/information#CD004314-cr-0009"><i class="icon corresponding-author fa fa-envelope"></i>João Costa</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/information/en#CD004314-sec-0112">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 26 October 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD004314.pub3">https://doi.org/10.1002/14651858.CD004314.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD004314-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004314-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004314-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004314-abs-0008">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD004314-abs-0001" lang="en"> <section id="CD004314-sec-0001"> <h3 class="title" id="CD004314-sec-0001">Background</h3> <p>This is an update of a Cochrane review first published in 2003. Cervical dystonia is the most common form of focal dystonia and is a disabling disorder characterised by painful involuntary head posturing. There are two available formulations of botulinum toxin, with botulinum toxin type A (BtA) usually considered the first line therapy for this condition. Botulinum toxin type B (BtB) is an alternative option, with no compelling theoretical reason why it might not be as‐ or even more effective ‐ than BtA. </p> </section> <section id="CD004314-sec-0002"> <h3 class="title" id="CD004314-sec-0002">Objectives</h3> <p>To compare the efficacy, safety and tolerability of botulinum toxin type A (BtA) versus botulinum toxin type B (BtB) in people with cervical dystonia. </p> </section> <section id="CD004314-sec-0003"> <h3 class="title" id="CD004314-sec-0003">Search methods</h3> <p>To identify studies for this review we searched the Cochrane Movement Disorders Group Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, reference lists of articles and conference proceedings. All elements of the search, with no language restrictions, were last run in October 2016. </p> </section> <section id="CD004314-sec-0004"> <h3 class="title" id="CD004314-sec-0004">Selection criteria</h3> <p>Double‐blind, parallel, randomised, placebo‐controlled trials (RCTs) comparing BtA versus BtB in adults with cervical dystonia. </p> </section> <section id="CD004314-sec-0005"> <h3 class="title" id="CD004314-sec-0005">Data collection and analysis</h3> <p>Two independent authors assessed records, selected included studies, extracted data using a paper pro forma, and evaluated the risk of bias. We resolved disagreements by consensus or by consulting a third author. We performed meta‐analyses using the random‐effects model, for the comparison BtA versus BtB to estimate pooled effects and corresponding 95% confidence intervals (95% CI). No prespecified subgroup analyses were carried out. The primary efficacy outcome was improvement on any validated symptomatic rating scale, and the primary safety outcome was the proportion of participants with adverse events. </p> </section> <section id="CD004314-sec-0006"> <h3 class="title" id="CD004314-sec-0006">Main results</h3> <p>We included three RCTs, all new to this update, of very low to low methodological quality, with a total of 270 participants. </p> <p>Two studies exclusively enrolled participants with a known positive response to BtA treatment. This raises concerns of population enrichment, with a higher probability of benefit from BtA treatment. None of the trials were free of for‐profit bias, nor did they provide information regarding registered study protocols. All trials evaluated the effect of a single Bt treatment session, and not repeated treatment sessions, using doses from 100 U to 250 U of BtA (all onabotulinumtoxinA, or Botox, formulations) and 5000 U to 10,000 U of BtB (rimabotulinumtoxinB, or Myobloc/Neurobloc). </p> <p>We found no difference between the two types of botulinum toxin in terms of overall efficacy, with a mean difference of ‐1.44 (95% CI ‐3.58 to 0.70) points lower on the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) for BtB‐treated participants, measured at two to four weeks after injection. The proportion of participants with adverse events was also not different between BtA and BtB (BtB versus BtA risk ratio (RR) 1.40; 95% CI 1.00 to 1.96). However, when compared to BtA, treatment with BtB was associated with an increased risk of one adverse events of special interest, namely treatment‐related sore throat/dry mouth (BtB versus BtA RR of 4.39; 95% CI 2.43 to 7.91). Treatment‐related dysphagia (swallowing difficulties) was not different between BtA and BtB (RR 2.89; 95% CI 0.80 to 10.41). The two types of botulinum toxin were otherwise clinically non‐distinguishable in all the remaining outcomes. </p> </section> <section id="CD004314-sec-0007"> <h3 class="title" id="CD004314-sec-0007">Authors' conclusions</h3> <p>The previous version of this review did not include any trials, since these were still ongoing at the time. Therefore, with this update we are able to change the conclusions of this review. There is low quality evidence that a single treatment session of BtA (specifically onabotulinumtoxinA) and a single treatment session of BtB (rimabotulinumtoxinB) are equally effective and safe in the treatment of adults with certain types of cervical dystonia. Treatment with BtB appears to present an increased risk of sore throat/dry mouth, compared to BtA. Overall, there is no clinical evidence from these single‐treatment trials to support or contest the preferential use of one form of botulinum toxin over the other. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD004314-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004314-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004314-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004314-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD004314-abs-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD004314-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD004314-abs-0005">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD004314-abs-0004">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD004314-abs-0003" lang="en"> <h3>A comparison of botulinum toxin type A versus botulinum toxin type B for involuntary positioning of the head, or cervical dystonia </h3> <p><b>The review question</b> </p> <p>We reviewed the evidence about the effect of botulinum toxin type A (BtA) compared to botulinum toxin type B (BtB) in people with involuntary positioning of the head, or cervical dystonia. This is an update of a previous Cochrane Review and we assessed the effectiveness (reduction in severity, disability and pain) and safety of BtA versus BtB in cervical dystonia. </p> <p><b>Background</b> </p> <p>Cervical dystonia, also called spasmodic torticollis, is a disease that causes undesired, uncontrollable, often painful, abnormal placement of the head. It is a relatively uncommon condition (affecting 57 to 280 people per million) that can be very disabling and can affect a person's quality of life negatively. In most cases the cause is unknown and no cure exists. Since cervical dystonia is normally a long‐term disease it requires long‐term treatment. </p> <p>Botulinum toxin (Bt) is a powerful, natural chemical that can cause severe paralysis (an inability to move in the part of the body where it is applied) in animals and humans<i>.</i> It can also be used to treat many conditions, in particular those with involuntary muscle contractions, such as cervical dystonia. Bt is delivered by injections into the muscles that contract to produce the disease. There are different types of Bt, not all are available for treating health conditions. BtA is typically the first‐used treatment in cervical dystonia, but botulinum toxin type B (BtB) is an alternative option. The relative strength of each Bt formulation is variable, and the cost for 200 units varies from GBP 198 to GBP 308. </p> <p><b>Study characteristics</b> </p> <p>We performed a rigorous search of the medical literature in October 2016 and found three studies that compared a single treatment session of BtA with BtB. These studies included a total of 270 participants, with on average a moderate disease impairment. The participants remained in the studies for a short period of time ‐ between 16 and 20 weeks after the treatment. The average age of people in the studies was 53.3 years, and they had had cervical dystonia for an average of 6.6 to 7.9 years before taking part in the trials. Most, 63.3%, of the people in the studies were women. All three of the studies were funded by drug manufacturers with possible interests in the results of the studies. </p> <p><b>Key results</b> </p> <p>The results show little or no difference between BtA and BtB in the main measures of overall improvement and safety, including the total number of adverse (unwanted or harmful) events. There was also little or no difference between BtA and BtB in the self‐evaluations reported by the study participants. Based on the results we would expect that, out of 1000 people with cervical dystonia treated with BtB, there would be 362 more people who experience dry mouth/sore throat compared to 1000 people treated with BtA. The studies which looked at the duration of effect showed little or no difference between BtA and BtB. None of the studies examined the impact of either Bt on quality of life. </p> <p><b>Quality of the evidence</b> </p> <p>All of the studies included participants that were different to the average person who suffers from cervical dystonia. To be included participants had to have a history of successful treatment with Bt. People with certain types of cervical dystonia, in particular the forms that make the head turn backward or forward, were not allowed to participate in the studies. </p> <p>Not enough participants were included across the studies for us to be completely confident in the results for the total number of adverse events, the self‐reported evaluations by participants or the pain assessment. </p> <p>The quality of the evidence for overall improvement and total number of adverse events was low. The quality of the evidence for more sore throat/dry mouth in people receiving BtB is moderate. The quality of the evidence where participants gave their self‐assessments is low. </p> <p>No definite conclusions can be drawn regarding overall safety and long‐term utility of BtA compared to BtB in cervical dystonia. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD004314-sec-0100" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004314-sec-0100">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004314-sec-0141">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD004314-sec-0100"></div> <h3 class="title" id="CD004314-sec-0101">Implications for practice</h3> <section id="CD004314-sec-0101"> <p>In this updated Cochrane Review we found that a single treatment session of BtA and a single treatment session of BtB are equally effective and well tolerated in the treatment of adults with certain types of cervical dystonia. Treatment with BtB is associated with an increased risk of sore throat/dry mouth when compared to treatment with BtA. Overall, there is no clinical evidence to support or not support the preferential use of one form of botulinum toxin over another. No conclusions can be drawn regarding individuals with predominant retrocollis or anterocollis, as these were mostly excluded from the clinical trials. </p> </section> <h3 class="title" id="CD004314-sec-0102">Implications for research</h3> <section id="CD004314-sec-0102"> <p>We have had access only to published research data from trials of botulinum toxin type A (BtA) versus BtB in cervical dystonia. It is difficult to determine which and how many resources should be invested in future research. </p> <p>It would be of interest if future studies comparing BtA and BtB were to use different formulations of BtA, namely abobotulinumtoxinA or incobotulinumtoxinA, or both, as the trials included in this review used only onabotulinumtoxinA. </p> <p>The net benefit of both a single BtA and BtB injection in the treatment of cervical dystonia has been established in the published trials. Nonetheless, further studies are needed to establish the relative effectiveness of different doses of specific botulinum toxin formulations, assessing efficacy, safety, duration of effect and quality of life across regimes. Because therapy typically requires optimising a dose for each patient rather than administering a fixed dose of botulinum toxin, such a line of research would be important to support physicians' management of doses and allow for a more solid and safe individualisation of patient treatment. Also to be determined is the added value, if any, of guidance methods (e.g. electromyography) in injecting botulinum toxin into the cervical muscles. </p> <p>The time to effect of BtA and BtB were not studied in any of the included studies, and as this may be a clinically relevant and differentiating factor between the two formulations, future research should endeavour to study this outcome. </p> <p>Future research concerning all formulations of botulinum neurotoxin should endeavour to establish clinical effectiveness not only based on changes from baseline, but also, preferably, based on validated measures of Minimal Clinically Important Difference/Change (<a href="./references#CD004314-bbs2-0017" title="BrożekJL , GuyattGH , SchünemannHJ . How a well‐grounded minimal important difference can enhance transparency of labelling claims and improve interpretation of a patient reported outcome measure. Health and Quality of Life Outcomes2006;4:69. ">Brożek 2006</a>). Research is required in order to establish such a parameter for the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS), currently the most widely used and disseminated clinical scale in the field. We are, however, aware of an effort to create a new clinical scale in dystonia ‐ the Comprehensive Cervical Dystonia Rating Scale (<a href="./references#CD004314-bbs2-0021" title="ComellaCL , FoxSH , BhatiaKP , PerlmutterJS , JinnahHA , ZurowskiM , et al. Development of the comprehensive Cervical Dystonia Rating Scale: methodology. Movement Disorders2015;2(2):135‐41. ">Comella 2015</a>), which will include a revision of the TWSTRS, to be named TWSTRS‐2, with a Minimal Clinically Important Change validation being planned. </p> <p>It is currently uncertain whether or not the clinical effectiveness of botulinum toxin decays over time, with repeated treatment sessions, and whether a possible loss of effectiveness occurs in all clinical domains. Another related aspect is the possible development of BtB‐non‐responsiveness, as there is no plausible theoretical reason why this would not occur, as it does for BtA. Future studies comparing BtA and BtB should address the comparative proportion of participants who develop clinical secondary non‐responsiveness to treatment. </p> <p>Finally, in conducting this systematic review we were faced with the fact that there is no defined core outcome set in cervical dystonia research, as there are for other areas (<a href="./references#CD004314-bbs2-0080" title="TugwellP , BoersM , BrooksP , SimonL , StrandV , IdzerdaL . OMERACT: an international initiative to improve outcome measurement in rheumatology. Trials2007;8:38. ">Tugwell 2007</a>). The definition of a set of core outcome measures to be included in future research, via well‐established methodology to determine the inclusion of patient‐reported outcomes (<a href="./references#CD004314-bbs2-0056" title="MacefieldRC , JacobsM , KorfageIJ , NicklinJ , WhistanceRN , BrookesST , et al. Developing core outcomes sets: methods for identifying and including patient‐reported outcomes (PROs). Trials2014;15:49. ">Macefield 2014</a>), would be relevant to promote research in this field, as well as to support the clinical effectiveness of botulinum toxin. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD004314-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD004314-sec-0022"></div> <div class="table" id="CD004314-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Botulinum toxin type A versus botulinum toxin type B for adults with cervical dystonia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Botulinum toxin type A compared to botulinum toxin type B for adults with cervical dystonia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with cervical dystonia<br/> <b>Settings:</b> hospital‐based, movement disorders clinics<br/> <b>Intervention:</b> botulinum toxin type A<br/> <b>Comparison:</b> botulinum toxin type B </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>What happens</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>With botulinum toxin type A</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>With botulinum toxin type B</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Difference</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall cervical dystonia improvement:</b> change from baseline to week 4 assessed with TWSTRS total score<br/> Scale (range, 0 to 85; more is worst)<br/> № of participants: 231<br/> (2 RCTs) </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9.1 TWSTRS units decrease</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.5 TWSTRS units decrease</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline was 1.44 TWSTRS units higher (0.7 lower to 3.58 higher) in the BtB group compared to the BtA group </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>LOW <sup>1, 2</sup> </b> </p> <p>Due to study limitations and imprecision</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There may be little or no difference in the overall cervical dystonia improvement</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants with adverse events</b> <br/> № of participants: 111<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.40</b> <br/> (1.00 to 1.96) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>47.3%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66.2%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.9% more adverse events<br/> (0 fewer to 45.4 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>LOW <sup>3</sup> </b> </p> <p>Due to imprecision</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There may be little or no difference in the risk of adverse events</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Subjective change as assessed by the patient at week 4</b> </p> <p>assessed with: PGA<br/> Scale (range, ‐4 to 4; more is worst)<br/> № of participants: 138<br/> (1 RCT) </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1.6 PGA units decrease</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4 PGA units decrease</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean subjective change in the BtB group was 0.2 PGA units lower (0.17 lower to 0.57 higher) compared to the BtA group </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>LOW <sup>2, 4</sup> </b> </p> <p>Due to study limitations and imprecision</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There may be little or no difference in subjective assessment</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cervical dystonia associated pain: change from baseline to week 2‐4</b> <br/> assessed with TWSTRS pain sub‐scale<br/> Scale (range, 0 to 20; more is worst)<br/> № of participants: 251<br/> (3 RCTs) </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2.63 TWSTRS units decrease</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.45 TWSTRS units decrease</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean change was 0.83 TWSTRS units higher (1.75 lower to 0.09 higher) in the BtB group compared to the BtA group </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>LOW <sup>2, 4</sup> </b> </p> <p>Due to study limitations and imprecision</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There may be little or no difference in the risk of cervical dystonia‐associated pain</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events: sore throat/dry mouth</b> <br/> № of participants: 212<br/> (2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>RR 4.39</b> <br/> (2.43 to 7.91) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10.5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46.7%</p> <p>(25.5 to 82.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35.5% more</p> <p>(15 more to 72.4 more)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>MODERATE<sup>2, 4</sup> </b> </p> <p>Due to study limitations and imprecision</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BtB treatment probably increases the risk of sore throat/dry mouth</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events: dysphagia</b> <br/> № of participants: 249<br/> (3 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.89</b> <br/> (0.80 to 10.41) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10.2%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.4%</p> <p>(8.1 to 100.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.2% more</p> <p>(2 fewer to 95.6 more)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>LOW <sup>2, 4, 5</sup> </b> </p> <p>Due to study limitations, imprecision, and inconsistency</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There may be little or no difference in the risk of dysphagia</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>BtA:</b> botulinum toxin type A; <b>BtB:</b> botulinum toxin type B; <b>CI:</b> confidence interval;<b>PGA:</b> Patient Global Assessment; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>TWSTRS:</b> Toronto Western Spasmodic Torticollis Rating Scale </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Serious imprecision: 95% CI includes both appreciable benefit and no effect. This means that we cannot conclusively state the equivalence of these two formulations. </p> <p><sup>2</sup> Serious study limitations: the limitations in the studies assessing this outcome are serious and affect our confidence in the accuracy of the effect estimate. </p> <p><sup>3</sup> Very serious imprecision: the total number of participants included was less than the number generated by a conventional sample size calculation for a single adequately powered equivalence trial. 95% CI includes both appreciable benefit and harm meaning that we cannot conclusively state the equivalence of these two formulations. </p> <p><sup>4</sup> Serious imprecision: the total number of participants included was less than the number generated by a conventional sample size calculation for a single adequately powered equivalence trial. </p> <p><sup>5</sup> Serious inconsistency: high degree of heterogeneity expressed by I<sup>2</sup> and low overlap of 95% CI. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD004314-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004314-sec-0023">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004314-sec-0119">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD004314-sec-0023"></div> <p>This review is an update of a previously published review in the <i>Cochrane Database of Systematic Reviews</i> 2003, Issue 3 (<a href="./references#CD004314-bbs2-0086" title="CostaJ , BorgesAA , Espírito‐SantoCC , FerreiraJ , CoelhoMM , MooreP , SampaioC . Botulinum toxin type A versus botulinum toxin type B for cervical dystonia. Cochrane Database of Systematic Reviews2003, Issue 3. [DOI: 10.1002/14651858.CD004314.pub2] ">Costa 2003</a>), evaluating the efficacy and safety of botulinum toxin type A (BtA) versus botulinum toxin type B (BtB) in the treatment of cervical dystonia. </p> <section id="CD004314-sec-0024"> <h3 class="title" id="CD004314-sec-0024">Description of the condition</h3> <p>See <a href="#CD004314-tbl-0002">Table 1</a> for glossary of terms. </p> <div class="table" id="CD004314-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary of terms</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Term</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Definition</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> BtA‐non‐responsive</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>People who do not experience the expected benefit from treatment with botulinum toxin type A </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Cervical dystonia or spasmodic torticollis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A common movement disorder in which people have abnormal movements or postures of the head and neck that they cannot control. It is frequently accompanied by social embarrassment and pain. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Chemodenervation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The process by which botulinum toxin causes muscular paralysis. Although all the anatomical elements necessary for muscular control are intact (i.e. nerve, synapse and muscle), there is a chemical process that disables the transmission of the electrical signal from the nerve to the muscle. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Dysphagia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Discomfort or difficulty when swallowing</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Electromyography</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>An examination that displays the electrical activity of muscles using pieces of metal attached to the skin or inserted into the muscle </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Non‐naive</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>People who have been treated in the past with botulinum toxin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Voluntary action</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Movements that are normally under a person's control, that can be started and stopped at will </p> </td> </tr> </tbody> </table> </div> <p>Dystonia is the third most common movement disorder, after Parkinson’s disease and essential tremor, with an overall prevalence of 164 per million (<a href="./references#CD004314-bbs2-0074" title="SteevesTD , DayL , DykemanJ , JetteN , PringsheimT . The prevalence of primary dystonia: a systematic review and meta‐analysis. Movement Disorders2012;27(14):1789‐96. ">Steeves 2012</a>). Dystonia syndromes are a group of disabling, painful disorders characterised by involuntary sustained or intermittent muscle contractions that cause abnormal, often repetitive, movements or postures of the face, neck, trunk or limbs (<a href="./references#CD004314-bbs2-0005" title="AlbaneseA , BhatiaK , BressmanSB , DelongMR , FahnS , FungVS , et al. Phenomenology and classification of dystonia: a consensus update. Movement Disorders2013;28(7):863‐73. ">Albanese 2013</a>). Dystonic movements are typically patterned or twisting, and are often initiated or worsened by voluntary action (<a href="./references#CD004314-bbs2-0005" title="AlbaneseA , BhatiaK , BressmanSB , DelongMR , FahnS , FungVS , et al. Phenomenology and classification of dystonia: a consensus update. Movement Disorders2013;28(7):863‐73. ">Albanese 2013</a>). These neurological disorders can be classified on the basis of topographic distribution, including focal dystonia (one body region, e.g. cervical dystonia (involuntary movements of head and neck) and blepharospasm (involuntary closure of the eyes)), segmental dystonia (two or more adjacent regions), multifocal dystonia (two or more nonadjacent regions), hemidystonia (ipsilateral regions (same side of the body)) and generalised dystonia (trunk and two or more other regions) (<a href="./references#CD004314-bbs2-0005" title="AlbaneseA , BhatiaK , BressmanSB , DelongMR , FahnS , FungVS , et al. Phenomenology and classification of dystonia: a consensus update. Movement Disorders2013;28(7):863‐73. ">Albanese 2013</a>; <a href="./references#CD004314-bbs2-0077" title="TarsyD , SimonD . Dystonia. New Egyptian Journal of Medicine2006;355:818‐29. ">Tarsy 2006</a>). </p> <p>Focal dystonia is a highly disabling movement disorder, with serious functional and social impairment. Close to half of the dystonia patient population quits work by the age of forty or retires early due to the condition, and 10 years later, only 25% of people are working compared to 62% of the general population (<a href="./references#CD004314-bbs2-0085" title="ZoonsE , DijkgraafMG , DijkJM , vanSchaikIN , TijssenMA . Botulinum toxin as treatment for focal dystonia: a systematic review of the pharmaco‐therapeutic and pharmaco‐economic value. Neurology2012;259(12):2519–26. ">Zoons 2012</a>). Moreover, health‐related quality of life is significantly diminished, mainly due to depression and anxiety, with scores comparable to people with multiple sclerosis, Parkinson’s disease or stroke (<a href="./references#CD004314-bbs2-0085" title="ZoonsE , DijkgraafMG , DijkJM , vanSchaikIN , TijssenMA . Botulinum toxin as treatment for focal dystonia: a systematic review of the pharmaco‐therapeutic and pharmaco‐economic value. Neurology2012;259(12):2519–26. ">Zoons 2012</a>). </p> <p>Cervical dystonia, also called spasmodic torticollis, is the most common form of adult‐onset focal dystonia, with estimates from population studies ranging from 57 per million in Europe (<a href="./references#CD004314-bbs2-0030" title="Epidemiological Study of Dystonia in Europe (ESDE) Collaborative Group. A prevalence study of primary dystonia in eight European countries. Journal of Neurology2000;247:787‐92. ">ESDE 2000</a>), to as high as 280 per million in the USA (<a href="./references#CD004314-bbs2-0052" title="JankovicJ , TsuiJ , BergeronC . Prevalence of cervical dystonia and spasmodic torticollis in the United States general population. Parkinsonism &amp; Related DisordersOctober 2007;13(7):411‐6. ">Jankovic 2006</a>). Typically, its onset occurs in the fifth decade of life (<a href="./references#CD004314-bbs2-0005" title="AlbaneseA , BhatiaK , BressmanSB , DelongMR , FahnS , FungVS , et al. Phenomenology and classification of dystonia: a consensus update. Movement Disorders2013;28(7):863‐73. ">Albanese 2013</a>), and it affects more women than men (<a href="./references#CD004314-bbs2-0027" title="DefazioG , JankovicJ , GielJL , PapapetropoulosS . Descriptive epidemiology of cervical dystonia. Tremor and Other Hyperkinetic Movements2013;3:tre‐03‐193‐4374‐2. ">Defazio 2013</a>). This condition is characterised by abnormal movements of head, neck, and shoulder, resulting in posturing of the head away from its normal central position (<a href="./references#CD004314-bbs2-0034" title="FoltzEL , KnoppLM , WardAA . Experimental spasmodic torticollis. Journal of Neurosurgery1959;16:55‐72. ">Foltz 1959</a>). It may present predominantly with sustained abnormal posture, spasm, jerks, tremor, or a combination of these features. Neck or shoulder pain, or both, occur in more than 70% of individuals with cervical dystonia (<a href="./references#CD004314-bbs2-0019" title="ChanJ , BrinMF , FanhS . Idiopathic cervical dystonia: clinical characteristics. Movement Disorders1991;6:119‐26. ">Chan 1991</a>; <a href="./references#CD004314-bbs2-0077" title="TarsyD , SimonD . Dystonia. New Egyptian Journal of Medicine2006;355:818‐29. ">Tarsy 2006</a>). </p> <p>Cervical dystonia can be classified according to the dominant head position, with the most common type involving horizontal turning, the so‐called rotatory (or simple) torticollis (<a href="./references#CD004314-bbs2-0005" title="AlbaneseA , BhatiaK , BressmanSB , DelongMR , FahnS , FungVS , et al. Phenomenology and classification of dystonia: a consensus update. Movement Disorders2013;28(7):863‐73. ">Albanese 2013</a>; <a href="./references#CD004314-bbs2-0019" title="ChanJ , BrinMF , FanhS . Idiopathic cervical dystonia: clinical characteristics. Movement Disorders1991;6:119‐26. ">Chan 1991</a>). Other common patterns include laterocollis (tilt to one side), retrocollis (tilt upwards resulting in neck extension) and anterocollis (tilt downwards resulting in neck flexion). Complex torticollis is a combination of these abnormal patterns, and is found relatively infrequently in clinical practice. </p> <p>The aetiology of most forms of dystonia is still not fully understood, with the exception of early‐onset dystonia, for which a hereditary aetiology is common (<a href="./references#CD004314-bbs2-0008" title="BalintB , BhatiaKP . Isolated and combined dystonia syndromes ‐ an update on new genes and their phenotypes. European Journal of Neurology2015;22(4):610‐7. ">Balint 2015</a>). In most cases of focal adult‐onset dystonia, such as cervical dystonia, the pathophysiology is generally considered to result from inhibition of the central nervous system (CNS) at multiple levels (<a href="./references#CD004314-bbs2-0040" title="HallettM . The neurophysiology of dystonia. Archives of Neurology1998;55(5):601‐3. ">Hallett 1998</a>), resulting in abnormal sensorimotor integration. Cervical dystonia can also be secondary to brain injury, infections of the CNS, drugs (such as levodopa or antipsychotics), toxins, vascular or neoplastic disorders, and may also be psychogenic (i.e. have a psychological origin) (<a href="./references#CD004314-bbs2-0005" title="AlbaneseA , BhatiaK , BressmanSB , DelongMR , FahnS , FungVS , et al. Phenomenology and classification of dystonia: a consensus update. Movement Disorders2013;28(7):863‐73. ">Albanese 2013</a>). Although most cases of cervical dystonia are currently classified as idiopathic (of unknown cause), it should be observed that some may come to be reclassified as inherited, since new gene discoveries are under investigation (<a href="./references#CD004314-bbs2-0005" title="AlbaneseA , BhatiaK , BressmanSB , DelongMR , FahnS , FungVS , et al. Phenomenology and classification of dystonia: a consensus update. Movement Disorders2013;28(7):863‐73. ">Albanese 2013</a>; <a href="./references#CD004314-bbs2-0008" title="BalintB , BhatiaKP . Isolated and combined dystonia syndromes ‐ an update on new genes and their phenotypes. European Journal of Neurology2015;22(4):610‐7. ">Balint 2015</a>). </p> <p>The natural course of cervical dystonia remains unclear. It usually develops gradually and worsens over the initial years. The clinical presentation in adults seldom progresses to generalised dystonia, although it often extends to contiguous body regions. For most individuals, cervical dystonia is a life‐long disorder, with only about 10% undergoing spontaneous remissions (<a href="./references#CD004314-bbs2-0049" title="JahnanshaniM , MarionM‐H , MarsdenCD . Natural history of adult‐onset idiopathic torticollis. Archives of Neurology1990;47:548‐52. ">Jahanshani 1990</a>). </p> <p>To date, no curative or disease‐modifying treatments are available for cervical dystonia.</p> </section> <section id="CD004314-sec-0025"> <h3 class="title" id="CD004314-sec-0025">Description of the intervention</h3> <p>Botulinum toxin (Bt) is a powerful biological toxin produced by the bacterium <i>Clostridium botulinum</i>. The active form of botulinum toxin is a polypeptide composed of two chains: a heavy chain (100 kDa) and a light chain (50 kDa), and by associating with certain auxiliary proteins (haemagglutinins and non‐haemagglutinins), the toxin forms a complex of variable size (<a href="./references#CD004314-bbs2-0071" title="SimpsonLL . Identification of the major steps in botulinum toxin action. Annual Review of Pharmacology and Toxicology2004;44:167‐93. ">Simpson 2004</a>). The nontoxic proteins aid the formation of neutralising antibodies, though beyond this their role is unclear (<a href="./references#CD004314-bbs2-0035" title="FrevertJ , DresslerD . Complexing proteins in botulinum toxin type A drugs: a help or a hindrance?. Biologics: Targets &amp; Therapy2010 Dec;4:325‐32. ">Frevert 2010</a>). Bt binds to peripheral cholinergic nerve terminals of the neuromuscular junction as well as sympathetic, parasympathetic and postganglionic terminals (<a href="./references#CD004314-bbs2-0071" title="SimpsonLL . Identification of the major steps in botulinum toxin action. Annual Review of Pharmacology and Toxicology2004;44:167‐93. ">Simpson 2004</a>). Bt, after binding to an acceptor protein, is endocytosed at the presynaptic membrane of acetylcholine nerve terminals (<a href="./references#CD004314-bbs2-0064" title="PellizzariR , RossettoO , SchiavoG , MontecuccoC . Tetanus and botulinum neurotoxins: mechanism of action and therapeutic uses. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences1999;354:259–68. ">Pellizzari 1999</a>). Through the action of the N‐terminal on the heavy‐chain, a pore is formed on the endocytic membrane, which permits the release of the light‐chain into the cytosol. This light chain, which is a zinc protease, performs the key action of botulinum toxin, by cleaving soluble N‐ethylmaleimide sensitive factor attachment receptor proteins (SNARE proteins) (<a href="./references#CD004314-bbs2-0064" title="PellizzariR , RossettoO , SchiavoG , MontecuccoC . Tetanus and botulinum neurotoxins: mechanism of action and therapeutic uses. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences1999;354:259–68. ">Pellizzari 1999</a>). </p> <p>SNAREs are docking proteins for acetylcholine vesicles that allow for the release of acetylcholine into the synaptic cleft (<a href="./references#CD004314-bbs2-0064" title="PellizzariR , RossettoO , SchiavoG , MontecuccoC . Tetanus and botulinum neurotoxins: mechanism of action and therapeutic uses. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences1999;354:259–68. ">Pellizzari 1999</a>). As the fusion of the vesicle membranes becomes inhibited, there is a temporary blockade of acetylcholine release at cholinergic synapses, causing a local chemodenervation. Temporary synapses are consequently formed via the process of axonal sprouting (<a href="./references#CD004314-bbs2-0028" title="DuchenLW . An electron microscopic study of the changes induced by botulinum toxin in the motor end‐plates of slow and fast skeletal muscle fibres of the mouse. Journal of the Neurological Sciences1971;14:47‐60. ">Duchen 1971</a>; <a href="./references#CD004314-bbs2-0047" title="HollandRL , BrownMC . Nerve growth in botulinum toxin poisoned muscles. Neuroscience1981;6:1167–79. ">Holland 1981</a>; <a href="./references#CD004314-bbs2-0053" title="JuzansP , ComellaJ , MolgoJ , FailleL , Angaut‐PetitD . Nerve terminal sprouting in botulinum type‐A treated mouse levator auris longus muscle. Neuromuscular Disorders1996;6(3):177‐85. ">Juzans 1996</a>). </p> <p>There are seven immunologically distinct botulinum toxin serotypes (labelled A to G). These different Bt serotypes cleave specific SNARE proteins. Serotype A cleaves SNARE protein SNAP 25 located on the inner membrane, and serotype B targets synaptobrevin located on the vesicular membrane (<a href="./references#CD004314-bbs2-0064" title="PellizzariR , RossettoO , SchiavoG , MontecuccoC . Tetanus and botulinum neurotoxins: mechanism of action and therapeutic uses. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences1999;354:259–68. ">Pellizzari 1999</a>). </p> <p>Botulinum toxin is injected into the muscles involved in dystonia, with or without guidance by either electromyography (EMG) or ultrasound. As a general rule, the overall dose, the number of muscles injected and the number of injection sites per muscle are tailored to the severity of the case and the mass of the muscle. Within roughly three months after injection of botulinum toxin into skeletal muscle, the nerve terminal resumes exocytosis, and the muscle returns to its baseline clinical function, showing a wearing off of response from the Bt injection (<a href="./references#CD004314-bbs2-0051" title="JankovicJ . Botulinum toxin in clinical practice. Journal of Neurology, Neurosurgery, and Psychiatry2004;75(7):951‐7. ">Jankovic 2004</a>). Eventually, the muscle paralysis subsides, and this is associated with the formation of new nerve sprouts capable of neurotransmission. Over time, synaptic activity resumes in the original nerve terminals, leading to sprout regression (<a href="./references#CD004314-bbs2-0026" title="dePaivaA , MeunierFA , MolgóJ , AokiKR , DollyJO . Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proceedings of the National Academy of Sciences of the United States of America1999;96:3200–5. ">de Paiva 1999</a>). </p> <p>Currently there are two commercially available botulinum toxin serotypes (BtA and BtB). The following products are commonly available (three BtA and one BtB): onabotulinumtoxinA (Botox, Allergan Inc, Irvine, CA, USA), abobotulinumtoxinA (Dysport/Reloxin/Azzalure, Ipsen Pharma, Boulogne Billancourt, France), incobotulinumtoxinA (Xeomin/Bocoture Merz GmbH, Frankfurt, Germany), and rimabotulinumtoxinB (Myobloc/Neurobloc, Solstice Neurosciences Inc, Louisville, KY, USA). Other BtA formulations are available in more restricted markets and are yet to receive a generic name: Prosigne/Lantox (Lanzhou Institute of Biological Products, China), PurTox (Mentor Worldwide LLC, Santa Barbara, CA, USA), and Neuronox (Medy‐Tox Inc, South Korea) (<a href="./references#CD004314-bbs2-0081" title="WalkerTJ , DayanSH . Comparison and overview of currently available neurotoxins. Journal of Clinical and Aesthetic Dermatology2014;7(2):31‐9. ">Walker 2014</a>). Each type of Bt has its own relative potency and it is estimated that 1 U of onabotulinumtoxinA roughly corresponds to 1 U of incobotulinumtoxinA, 3 U to 5 U of abobotulinumtoxinA, and 50 U of rimabotulinumtoxinB (<a href="./references#CD004314-bbs2-0011" title="BentivoglioAR , DelGrandeA , PetraccaM , Tamara IalongoT , RicciardiL . Clinical differences between botulinum neurotoxin type A and B. Toxicon2015;107:77‐84. [DOI: http://dx.doi.org/10.1016/j.toxicon.2015.08.001] ">Bentivoglio 2015</a>). The treatment cost per patient for each of the formulations is highly variable, and depends greatly on the country and individual characteristics of the people being treated, including responsiveness to Bt and number of muscles affected. Having in mind the 2016 prices per vial for each of the formulations currently available in the UK, and their relative potencies, 200 U of onabotulinumtoxinA cost GBP 276, 200 U of incobotulinumtoxinA cost GBP 260, 600 U to 1000 U of abobotulinumtoxinA cost GBP 184 to GBP 308, and 10,000 U of rimabotulinumtoxinB cost GBP 198 (<a href="./references#CD004314-bbs2-0012" title="British National Formulary. Botulinum toxin type A. National Institute for Health and Care ExcellenceMay 2016. [http://www.evidence.nhs.uk/formulary/bnf/current/4‐central‐nervous‐system/49‐drugs‐used‐in‐parkinsonism‐and‐related‐disorders/493‐drugs‐used‐in‐essential‐tremor‐chorea‐tics‐and‐related‐disorders/torsion‐dystonias‐and‐other‐involuntary‐movements/botulinum‐toxin‐type‐a] ">BNF 2016a</a>; <a href="./references#CD004314-bbs2-0013" title="British National Formulary. Botulinum toxin type B. National Institute for Health and Care ExcellenceMay 2016. [http://www.evidence.nhs.uk/formulary/bnf/current/4‐central‐nervous‐system/49‐drugs‐used‐in‐parkinsonism‐and‐related‐disorders/493‐drugs‐used‐in‐essential‐tremor‐chorea‐tics‐and‐related‐disorders/torsion‐dystonias‐and‐other‐involuntary‐movements/botulinum‐toxin‐type‐b] ">BNF 2016b</a>). </p> </section> <section id="CD004314-sec-0026"> <h3 class="title" id="CD004314-sec-0026">How the intervention might work</h3> <p>The therapeutic potential of all Bt serotypes derives from their ability to inhibit the release of acetylcholine from the presynaptic nerve terminal into the synaptic cleft, causing local chemodenervation (<a href="./references#CD004314-bbs2-0051" title="JankovicJ . Botulinum toxin in clinical practice. Journal of Neurology, Neurosurgery, and Psychiatry2004;75(7):951‐7. ">Jankovic 2004</a>). In addition to this, recent research has also suggested that Bt is active at multiple levels, namely sensory nerve terminals, and muscle spindles, which leads to a reduction in sensory input and fewer muscle contractions (<a href="./references#CD004314-bbs2-0032" title="FilippiGM , ErricoP , SantarelliR , BagoliniB , ManniE . Botulinum A toxin effects on rat jaw muscle spindles. Acta Oto‐laryngologica1993;113:400–4. ">Filippi 1993</a>; <a href="./references#CD004314-bbs2-0058" title="MatakI , LackovićZ . Botulinum toxin A, brain and pain. Progress in Neurobiology2014;119‐20:39–59. ">Matak 2014</a>; <a href="./references#CD004314-bbs2-0067" title="RosalesRL , ArimuraK , TakenakaS , OsameM . Extrafusal and intrafusal muscle effects in experimental botulinum toxin‐A injection. Muscle &amp; Nerve1996;19:488–96. ">Rosales 1996</a>; <a href="./references#CD004314-bbs2-0068" title="RosalesRL , DresslerD . On muscle spindles, dystonia and botulinum toxin. European Journal of Neurology2010;17:71–80. ">Rosales 2010</a>). </p> <p>It has also been suggested that cortical reorganisation may result from changes in the spinal cord, brainstem and central nervous pathways (<a href="./references#CD004314-bbs2-0063" title="PalomarFJ , MirP . Neurophysiological changes after intramuscular injection of botulinum toxin. Clinical Neurophysiology2012;123(1):54–60. ">Palomar 2012</a>). Animal research has shown the presence of supra‐therapeutic levels of Bt by way of retrograde axonal transport and penetration of the central nervous system (<a href="./references#CD004314-bbs2-0007" title="AntonucciF , RossiC , GianfranceschiL , RossettoO , CaleoM . Long‐distance retrograde effects of botulinum neurotoxin. Journal of Neuroscience2008;28:3689–96. ">Antonucci 2008</a>; <a href="./references#CD004314-bbs2-0014" title="BoroffDA , ChenGS . On the question of permeability of the blood–brain barrier to botulinum toxin. International Archives of Allergy and Applied Immunology1975;48:495–504. ">Boroff 1975</a>). However, Bt has not been shown to penetrate the blood‐brain barrier in humans. </p> <p>Until recently, SNARE proteins were considered to be the only target‐molecules of Bt. Thus, it was widely accepted that the therapeutic and toxic actions of Bt were exclusively mediated by SNARE cleavage preventing the release of synaptic neurotransmitters. However, recent studies have suggested that a number of Bt actions might not be mediated by SNARE cleavage, specifically regarding neuroexocytosis, cell cycle (division) and apoptosis (programmed cell death), neuritogenesis (formation of nerves) and gene expression (<a href="./references#CD004314-bbs2-0059" title="MatakI , LackovićZ . Botulinum neurotoxin type A: actions beyond SNAP‐25?. Toxicology2015;335:79‐84. ">Matak 2015</a>). The existence of unknown Bt molecular targets and modulation of unknown signalling pathways is a possibility that may prove to be relevant pharmacologically. </p> </section> <section id="CD004314-sec-0027"> <h3 class="title" id="CD004314-sec-0027">Why it is important to do this review</h3> <p>BtA is the toxin serotype that has been most intensively studied and approved for the treatment of a large number of focal dystonias. BtA is considered the first line therapy for cervical dystonia (<a href="./references#CD004314-bbs2-0005" title="AlbaneseA , BhatiaK , BressmanSB , DelongMR , FahnS , FungVS , et al. Phenomenology and classification of dystonia: a consensus update. Movement Disorders2013;28(7):863‐73. ">Albanese 2013</a>). However, not all people with cervical dystonia have an adequate clinical response. Primary non‐response to Bt is seen in cases where the first and subsequent treatment cycles do not elicit a response. Cases of secondary non‐response, however, respond to initial treatment, but over the course of multiple treatment cycles, this effect wanes and is eventually lost. Secondary non‐responsiveness is partially explained by the formation of neutralising antibodies, though it is worth noting that there are cases of secondary non‐responders without positive antibody titers (<a href="./references#CD004314-bbs2-0041" title="HannaPA , JankovicJ . Mouse bioassay versus western blot assay for botulinum toxin antibodies: correlation with clinical response. Neurology1998;50(6):1624‐9. ">Hanna 1998</a>; <a href="./references#CD004314-bbs2-0054" title="LangeO , BigalkeH , DenglerR , WegnerF , deGrootM , WohlfarthK . Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing?. Clinical Neuropharmacology2009;32(4):213‐8. ">Lange 2009</a>), as well as cases with positive titers with a maintained clinical response to Bt (<a href="./references#CD004314-bbs2-0016" title="BrinMF , ComellaCL , JankovicJ , LaiF , NaumannM , CD‐017 BoNTA Study Group. Long‐term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Movement Disorders2008;23(10):1353‐60. ">Brin 2008</a>; <a href="./references#CD004314-bbs2-0061" title="MüllerK , MixE , Adib SaberiF , DresslerD , BeneckeR . Prevalence of neutralising antibodies in patients treated with botulinum toxin type A for spasticity. Journal of Neural Transmission2009;116(5):579‐85. ">Müller 2009</a>). An estimated 4% to 20% of people with cervical dystonia develop neutralising antibodies to the toxin (<a href="./references#CD004314-bbs2-0015" title="BrashearA . Botulinum toxin serotype A for cervical dystonia—an assessment. US Neurology2008;4(2):58‐61. ">Brashear 2008</a>; <a href="./references#CD004314-bbs2-0031" title="FabbriM , LeodoriG , FernandesRM , BhidayasiriR , MartiMJ , ColosimoC , et al. Neutralizing antibody and botulinum toxin therapy: a systematic review and meta‐analysis. Neurotoxicity Research2015;29:105‐17. [PUBMED: 26467676] ">Fabbri 2015</a>), and if secondary non‐responsiveness occurs, it is partially related to the protein load, with a higher protein load per dose generating higher antibody titers (<a href="./references#CD004314-bbs2-0010" title="BeneckeR . Clinical Relevance of Botulinum Toxin Immunogenicity. BioDrugs2012;26(2):e1‐e9. ">Benecke 2012</a>; <a href="./references#CD004314-bbs2-0035" title="FrevertJ , DresslerD . Complexing proteins in botulinum toxin type A drugs: a help or a hindrance?. Biologics: Targets &amp; Therapy2010 Dec;4:325‐32. ">Frevert 2010</a>). </p> <p>At the present time, BtB is the only approved non‐BtA formulation available for the treatment of cervical dystonia in the European Union and North America. Both BtA and BtB have been shown to be efficacious in comparison to placebo in the treatment of adults with cervical dystonia (<a href="./references#CD004314-bbs2-0024" title="CostaJ , Espírito‐SantoC , BorgesA , FerreiraJJ , CoelhoM , MooreP , et al. Botulinum toxin type A therapy for cervical dystonia. Cochrane Database of Systematic Reviews2005, Issue 1. [DOI: 10.1002/14651858.CD003633.pub2; PUBMED: 15674910] ">Costa 2005</a>; <a href="./references#CD004314-bbs2-0057" title="MarquesRE , DuarteGS , RodriguesFB , CastelãoM , FerreiraJ , SampaioC , et al. Botulinum toxin type B for cervical dystonia. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD004315.pub3; PUBMED: 27176573] ">Marques 2016</a>), although with apparently different safety profiles. In the context of cervical dystonia, BtB is of particular interest as a treatment option for individuals who are non‐responsive to BtA (<a href="./references#CD004314-bbs2-0025" title="CullisPA , BarnesM , DuaneD , ChenRE , FreemanA , FrossR , et al. Safety and tolerability of repeated doses of Neurobloc (Botulinum toxin type B) in patients with cervical dystonia: an open‐label, dose‐escalation study. Movement Disorders2000;15 (Suppl 2):29. ">Cullis 2000</a>; <a href="./references#CD004314-bbs2-0029" title="EleopraR , TugnoliV , RossettoO , MontecuccoC , DeGrandisD . Botulinum neurotoxin serotype C: a novel effective botulinum toxin therapy in human. Neuroscience Letters1997;224(2):91‐4. ">Eleopra 1997</a>; <a href="./references#CD004314-bbs2-0038" title="GreenePE , FahnS . Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A. Movement Disorders1993;8(4):479‐83. ">Greene 1993</a>). </p> <p>Although different Bt subtypes have different molecular targets, to date we know of no evidence from systematic reviews or randomised controlled trials that presents conclusive evidence regarding the comparative effectiveness of BtA and BtB for treating cervical dystonia. </p> <p>This is an update of a Cochrane systematic review that previously assessed this question. The original review failed to included any trials addressing clinical comparability of BtA versus BtB in cervical dystonia. Since the release of the original review, three trials have been published (<a href="./references#CD004314-bbs2-0001" title="ComellaCL , JankovicJ , ShannonKM , TsuiJ , SwensonM , LeurgansS , et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology2005;65:1423‐9. [DOI: 10.1212/01.wnl.0000183055.81056.5c] ">Comella 2005</a>; <a href="./references#CD004314-bbs2-0002" title="PappertEJ , GermansonT . Botulinum toxin type B vs. type A in toxin‐naïve patients with cervical dystonia: randomized double‐blind, noninferiority trial. Movement Disorders2008;23:510‐7. ">Pappert 2008</a>; <a href="./references#CD004314-bbs2-0003" title="TintnerR , GrossR , WinzerUF , SmalkyKA , JankovicJ . Autonomic function after botulinum toxin type A or B: a double‐blind, randomized trial. Neurology2005;65:765‐7. ">Tintner 2005</a>). Furthermore, Cochrane’s criteria for evaluating studies' risk of bias and quality of evidence have evolved and been updated. Therefore, the authors consider it important to update this review. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD004314-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004314-sec-0028">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004314-sec-0124">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD004314-sec-0028"></div> <p>To compare the efficacy, safety and tolerability of botulinum toxin type A versus botulinum toxin type B in people with cervical dystonia. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD004314-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004314-sec-0029">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004314-sec-0125">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD004314-sec-0029"></div> <section id="CD004314-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD004314-sec-0031"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs), blinded, single or multiple dose, parallel‐designed, of any duration, assessing the efficacy or safety, or both, of treatment with BtA versus BtB in adults with cervical dystonia were eligible for inclusion in this review. If trials had used inadequate randomisation or allocation concealment methods we would have included these only in the safety analyses. Non‐parallel study designs, namely cross‐over trials, were excluded in this updated version of the review, due to uncertainty about whether this type of study design was appropriate for studying people with cervical dystonia, as well as methodological concerns with regard to detection and performance bias. </p> </section> <section id="CD004314-sec-0032"> <h4 class="title">Types of participants</h4> <p>Adults (i.e. 18 years of age and over), in any setting, with a clinical diagnosis, made by any physician, specialist or otherwise, of idiopathic cervical dystonia. We included trials that enrolled participants with any form of cervical dystonia, and additional or more widespread dystonias. Participants could have prior exposure to BtA or BtB, and could be taking any concomitant medications, if on stable regimens. </p> <p>There were no restrictions regarding the number of participants recruited to trials, or the number of recruitment centres. </p> </section> <section id="CD004314-sec-0033"> <h4 class="title">Types of interventions</h4> <p>Intramuscular injections of BtA compared to BtB. We allowed all administration schedules and injection techniques, performed with or without guidance by either EMG or ultrasound. </p> </section> <section id="CD004314-sec-0034"> <h4 class="title">Types of outcome measures</h4> <section id="CD004314-sec-0035"> <h5 class="title">Primary outcomes</h5> <section id="CD004314-sec-0036"> <h6 class="title">Primary efficacy outcome</h6> <p>Overall improvement on any validated symptomatic rating scale, such as Tsui scale, Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS), and Cervical Dystonia Severity Scale (CDSS), measured between weeks 3 and 6 post‐injection. </p> </section> <section id="CD004314-sec-0037"> <h6 class="title">Primary safety outcome</h6> <p>Proportion of participants with any adverse event, measured at any point during study follow‐up. </p> </section> </section> <section id="CD004314-sec-0038"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD004314-list-0001"> <li> <p>Change in subjective evaluation of clinical status evaluated by both patients and clinicians, as assessed with validated assessment tools such as the Patient Subjective Assessment of Change, Patient Global Assessment of Improvement, Patient Evaluation of Global Response (PEGR), Patient and Physician Global Assessment of Change, Investigator Global Assessment of Efficacy (IGAE), Physician Global Assessment of Change (PGAC), and visual analogue scale (VAS) for symptom severity, measured between weeks 3 and 6 post‐injection. </p> </li> <li> <p>Changes in pain scores, as assessed with validated assessment tools such as the Patient Assessment of Pain, TWSTRS‐pain sub‐scale score, and VAS Pain score, measured between weeks 2 and 6 post‐injection. </p> </li> <li> <p>Changes in quality of life assessments, as assessed with validated assessment tools such as the Short Form 36 (SF‐36) quality‐of‐life questionnaire, measured at any point during study follow‐up. </p> </li> <li> <p>Numbers of participants with adverse events of special interest, such as dysphagia, sore throat, and local injection‐site pain, measured at any point during study follow‐up. </p> </li> <li> <p>Duration of effect, assessed by the number of days until need for reinjection or effect waning. </p> </li> </ul> </p> </section> </section> </section> <section id="CD004314-sec-0039"> <h3 class="title">Search methods for identification of studies</h3> <p>For this update, we expanded the search strategy to capture all the search terms for BtA and BtB formulations that were available at the time of the search. We designed the search strategy to include other botulinum toxin formulations and other dystonic disorders that were also under revision by our group. </p> <section id="CD004314-sec-0040"> <h4 class="title">Electronic searches</h4> <p>We ran the final search for the original version of this review in June 2003, based on the search strategy developed for the Movement Disorders Group to identify all papers from 1977, the first year botulinum toxin was used therapeutically in any condition. The search for the current update was run for the last time in October 2016. </p> <p>For the identification of studies considered for inclusion in this review, we developed detailed search strategies for each database searched. Please see <a href="./appendices#CD004314-sec-0106">Appendix 1</a> for the CENTRAL strategy, <a href="./appendices#CD004314-sec-0107">Appendix 2</a> for the MEDLINE search strategy, and <a href="./appendices#CD004314-sec-0108">Appendix 3</a> for the EMBASE strategy. </p> <p>We assessed non‐English language papers, translated them as necessary and evaluated them for inclusion. </p> <p>We did not search trial registries.</p> <section id="CD004314-sec-0041"> <h5 class="title">Databases searched</h5> <p> <ul id="CD004314-list-0002"> <li> <p>Cochrane Movement Disorders Group trials register (June 2003);</p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; the Cochrane Library 2016, Issue 11); </p> </li> <li> <p>MEDLINE (1977 to 6 October 2016);</p> </li> <li> <p>Embase (1977 to 6 October 2016).</p> </li> </ul> </p> </section> </section> <section id="CD004314-sec-0042"> <h4 class="title">Searching other resources</h4> <p>The search strategy also included:</p> <p> <ul id="CD004314-list-0003"> <li> <p>searches through reference lists of located trials and review articles concerning botulinum toxin; </p> </li> <li> <p>handsearch of abstracts of international congresses relevant in the fields of movement disorders and botulinum toxins, i.e. American Academy of Neurology, Movement Disorders Society, International Association of Parkinsonism and Related Disorders, and International Neurotoxin Association (1985 to October 2016); </p> </li> <li> <p>personal communication with other researchers in the field;</p> </li> <li> <p>contact with drug manufacturers;</p> </li> <li> <p>whenever necessary, we contacted authors of published trials for further information and unpublished data. </p> </li> </ul> </p> </section> </section> <section id="CD004314-sec-0043"> <h3 class="title" id="CD004314-sec-0043">Data collection and analysis</h3> <section id="CD004314-sec-0044"> <h4 class="title">Selection of studies</h4> <p>Two authors independently screened all titles and abstracts identified from searches to determine which met the inclusion criteria. We retrieved in full text any papers identified as potentially relevant by at least one author, or those without an available abstract. Two review authors independently screened full text articles, with discrepancies resolved by discussion and by consulting a third author where necessary to reach consensus. We collated duplicate publications and present these by individual study. The screening and selection process is outlined in a PRISMA flow chart (<a href="./references#CD004314-bbs2-0055" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GotzschePC , IoannidisJP , et al. The PRISMA statement for reporting systematic reviews and meta‐analyses of studies that evaluate health care interventions: explanation and elaboration. PLOS Medicine2009;6:e1000100. ">Liberati 2009</a>), see <a href="#CD004314-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD004314-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="BtA vs BtB in Cervical Dystonia Flow Diagram." data-id="CD004314-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/image_n/nCD004314-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>BtA vs BtB in Cervical Dystonia Flow Diagram.</p> </div> </div> </div> </section> <section id="CD004314-sec-0045"> <h4 class="title">Data extraction and management</h4> <p>Two review authors extracted data independently from included studies using a piloted data extraction form. Any discrepancies were resolved by discussion until consensus was reached, or through consultation with a third author where necessary. The authors extracted data on the following items from each study. </p> <p> <ul id="CD004314-list-0004"> <li> <p>Participants: inclusion and exclusion criteria, demographics and clinical baseline characteristics, number and reasons for withdrawals, exclusions and loss to follow‐up, if any. </p> </li> <li> <p>Interventions: full description of intervention, duration of treatment period and follow‐up, providers, and co‐interventions, if any. </p> </li> <li> <p>Comparisons: number of participants randomised to each arm, compliance and dropouts, reasons for dropouts, and ability to perform an intention‐to‐treat analysis. </p> </li> <li> <p>Outcomes: definition of outcomes, use of validated measurement tools, time point measurements, change from baseline or post‐interventional measures, and missing outcomes, if any. </p> </li> <li> <p>Study design: interventional, randomised, controlled, double‐blind.</p> </li> </ul> </p> </section> <section id="CD004314-sec-0046"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed the risk of bias of included studies according to the domains described in the Cochrane tool for assessing risk of bias (<a href="./references#CD004314-bbs2-0045" title="HigginsJPT , AltmanDG , Sterne JACeditor(s) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011b</a>), and classified the risk of bias for each domain as high, unclear, or low, and the overall assessment as high or low. We assessed two further domains, which are described below: 'for‐profit bias' and 'enriched population'. We used the following definitions for each domain in the 'Risk of bias' assessment. </p> <section id="CD004314-sec-0047"> <h5 class="title">Random sequence generation</h5> <p> <ul id="CD004314-list-0005"> <li> <p>Low risk of bias: the study performed sequence generation using computer random number generation or a random number table. Drawing lots, tossing a coin, shuffling cards, and throwing dice were adequate if an independent person not otherwise involved in the study performed them. </p> </li> <li> <p>Unclear risk of bias: the study authors did not report the sequence generation method.</p> </li> <li> <p>High risk of bias: the sequence generation method was not random.</p> </li> </ul> </p> </section> <section id="CD004314-sec-0048"> <h5 class="title">Allocation concealment</h5> <p> <ul id="CD004314-list-0006"> <li> <p>Low risk of bias: participants and investigators enrolling participants could not foresee assignment because one of the following, or an equivalent method, was used to conceal allocation: central allocation, sequentially numbered drug containers of identical appearance; sequentially numbered, opaque, sealed envelopes. </p> </li> <li> <p>Unclear risk of bias: insufficient information available to permit a judgement of ‘low risk’ or ‘high risk’. </p> </li> <li> <p>High risk of bias: participants or investigators enrolling participants could possibly foresee assignments and thus introduce selection bias. </p> </li> </ul> </p> <p>In addition to these criteria, we considered the implications of baseline imbalances in prognostic factors affecting the trial outcomes, as these may lead to selection bias (<a href="./references#CD004314-bbs2-0023" title="CorbettMS , HigginsJP , WoolacottNF . Assessing baseline imbalance in randomised trials: implications for the Cochrane risk of bias tool. Research Synthesis Methods2014;5(1):79‐85. ">Corbett 2014</a>). </p> </section> <section id="CD004314-sec-0049"> <h5 class="title">Blinding of participants and personnel</h5> <p> <ul id="CD004314-list-0007"> <li> <p>Low risk of bias: either of the following: no blinding or incomplete blinding, but the review authors judge that the outcome is not likely to be influenced by lack of blinding; or blinding of participants and key study personnel ensured, and it is unlikely that the blinding could have been broken. </p> </li> <li> <p>Unclear risk of bias: any of the following: insufficient information available to permit a judgement of ‘low risk’ or ‘high risk’; or the trial did not address this outcome. </p> </li> <li> <p>High risk of bias: either of the following: no blinding or incomplete blinding, and the outcome is likely to be influenced by lack of blinding; or blinding of key study participants and personnel attempted, but likely that the blinding could have been broken, and the outcome is likely to be influenced by lack of blinding. </p> </li> </ul> </p> </section> <section id="CD004314-sec-0050"> <h5 class="title">Blinded outcome assessment</h5> <p>We considered blinding separately for different outcomes, as appropriate, and, to aid in the process, divided the domain into two categories: subjective and objective assessment. </p> <p> <ul id="CD004314-list-0008"> <li> <p>Low risk of bias: either of the following: no blinding of outcome assessment, but the review authors judge that the outcome measurement is not likely to be influenced by lack of blinding; or blinding of outcome assessment ensured, and it is unlikely that the blinding could have been broken. </p> </li> <li> <p>Unclear risk of bias: any of the following: insufficient information available to permit a judgement of ‘low risk’ or ‘high risk’; or the trial did not address this outcome. </p> </li> <li> <p>High risk of bias: either of the following: no blinding of outcome assessment, and the outcome measurement is likely to be influenced by lack of blinding; or blinding of outcome assessment, but likely that the blinding could have been broken, and the outcome measurement is likely to be influenced by lack of blinding. </p> </li> </ul> </p> </section> <section id="CD004314-sec-0051"> <h5 class="title">Incomplete outcome data</h5> <p> <ul id="CD004314-list-0009"> <li> <p>Low risk of bias: missing data were unlikely to make treatment effects depart from plausible values. The study used sufficient methods, such as multiple imputation, to handle missing data. </p> </li> <li> <p>Unclear risk of bias: there was insufficient information available to assess whether missing data in combination with the method used to handle missing data were likely to induce bias to the results. </p> </li> <li> <p>High risk of bias: the results were likely to be biased due to missing data.</p> </li> </ul> </p> </section> <section id="CD004314-sec-0052"> <h5 class="title">Selective outcome reporting</h5> <p> <ul id="CD004314-list-0010"> <li> <p>Low risk: the trial reported the following predefined outcomes: if the original trial protocol was available, the outcomes reported by the trial were listed in that protocol; if the trial protocol was obtained from a trial registry, the outcomes reported by the trial should have been those enumerated in the original protocol if the trial protocol was registered before or at the time that the trial was begun. </p> </li> <li> <p>Unclear risk: the study authors did not report all predefined outcomes fully, or it is unclear whether the study authors recorded data on outcomes or not. </p> </li> <li> <p>High risk: the study authors did not report one or more predefined outcomes; if the trial protocol was registered after the trial was begun, we did not consider those outcomes to be reliable. </p> </li> </ul> </p> </section> <section id="CD004314-sec-0053"> <h5 class="title">For‐profit bias</h5> <p>In order to assess the study source of funding, this domain was added in place of the ‘other bias’ domain. </p> <p> <ul id="CD004314-list-0011"> <li> <p>Low risk of bias: the trial appears to be free of industry sponsorship or other type of for‐profit support that may manipulate the trial design, conductance, or reporting of trial results. </p> </li> <li> <p>Unclear risk of bias: the trial may or may not be free of for‐profit bias as the trial does not provide any information about clinical trial support or sponsorship. </p> </li> <li> <p>High risk of bias: the trial is sponsored by industry or received other type of for‐profit support. </p> </li> </ul> </p> </section> <section id="CD004314-sec-0054"> <h5 class="title">Enriched population</h5> <p>Because the clinical effect of botulinum toxin treatment is easily perceived, Bt non‐naive participants are likely to recognise the presence or absence of clinical effects, or frequent adverse events, or both, effectively revealing the respective allocation arm. It is also relevant that, by preferentially including responders to Bt or excluding non‐responders to Bt, there is an increased likelihood that these participants respond more favourably to Bt than a naive population would. We opted to subdivide this domain in two: preferential enrolment of known positive responders to Bt; and exclusion of known poor responders to Bt. </p> <p> <ul id="CD004314-list-0012"> <li> <p>Low risk of bias: at least 70% of trial participants were Bt‐naive; the trial did not exclude any particular forms of cervical dystonia. </p> </li> <li> <p>Unclear risk of bias: the trial did not make explicit the percentage of participants who were known responders to Bt. </p> </li> <li> <p>High risk of bias: arbitrarily defined as more than 30% of participants non‐naive to Bt; explicit exclusion of people with forms of cervical dystonia known to have a poor response to Bt, namely people with pure anterocollis and retrocollis. </p> </li> </ul> </p> </section> </section> <section id="CD004314-sec-0055"> <h4 class="title">Measures of treatment effect</h4> <p>We compared disease symptoms at baseline to disease symptoms in weeks 2 to 4 post‐injection in the BtA and BtB arms. We extracted continuous outcomes whenever possible. These data were then pooled from the studies, where adequate, and used for comparison. </p> <section id="CD004314-sec-0056"> <h5 class="title">Dichotomous data</h5> <p>We based analysis of these data on the number of events and the number of people assessed in the intervention and comparison groups. We used these to calculate the risk ratio (RR) and 95% confidence interval (CI). </p> </section> <section id="CD004314-sec-0057"> <h5 class="title">Continuous data</h5> <p>We based analysis of these data on the mean, standard deviation (SD) and number of people assessed for both the intervention and comparison groups to calculate mean difference (MD) and 95% CI. Where the MD was reported without individual group data, we used this to report the study results. If more than one study measured the same outcome using different validated tools, we calculated the standardised mean difference (SMD), namely Hedges’ (adjusted) <i>g</i> (<a href="./references#CD004314-bbs2-0042" title="HedgesLV , OlkinI . Statistical Methods for Meta‐Analysis. Academic Press, Inc, 1985. ">Hedges 1985</a>), and 95% CI. For interpretation of effect sizes with SMDs, we used a rule of thumb to define a small effect (SMD = 0.2), a moderate effect (SMD = 0.5), or a large effect (SMD = 0.8) (<a href="./references#CD004314-bbs2-0020" title="CohenJ . Statistical Power Analysis in the Behavioral Sciences. 2nd Edition. Hillsdale (NJ): Lawrence Erlbaum Associates, Inc, 1988. ">Cohen 1988</a>). If necessary for comparison, we dichotomised rating scales using each study author's own criteria for improvement or no improvement. </p> </section> <section id="CD004314-sec-0058"> <h5 class="title">Time‐to‐event data</h5> <p>We planned to analyse these data based on log hazard ratios and standard errors obtained from results of Cox proportional hazards regression models. We had planned to use these in order to calculate a hazard ratio (HR) and 95% CI. </p> </section> </section> <section id="CD004314-sec-0059"> <h4 class="title">Unit of analysis issues</h4> <p>Whenever the included studies had multiple arms with different dosages of one or two of the botulinum toxins, we combined all groups to create a single pair‐wise comparison, using the Review Manager 5 (RevMan 5) calculator (<a href="./references#CD004314-bbs2-0066" title="The Nordic Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>), according to the methods suggested by Cochrane (<a href="./references#CD004314-bbs2-0046" title="HigginsJPT , DeeksJJ , Altman DGeditor(s) . Chapter 16: Special topics in statistics. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011c</a>). We also would have opted to create a single pair‐wise comparison in case of multiple treatment groups using different interventions (e.g. onabotulinumtoxinA and abobotulinumtoxinA) if these were compared to the same comparator. </p> <p>This method combines all relevant experimental intervention groups of the study into a single group, and combines all relevant control intervention groups into a single control group. This approach avoided the duplication of the control group that would happen if multiple comparisons (e.g. BtX dose1 versus BtY; BtX dose2 versus BtY) were included in the meta‐analysis, as well as the loss of information if one dosage group was chosen to the detriment of the others. If applicable, we planned to explore the effect of dosage in subgroup analysis. </p> <p>For dichotomous outcomes, both the sample sizes and the numbers of people with events would have been summed across groups. For continuous outcomes, means and standard deviations could be combined using a pooled mean or SD (<a href="./references#CD004314-bbs2-0044" title="HigginsJP , Deeks JJeditor(s) . Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>; <a href="./references#CD004314-bbs2-0046" title="HigginsJPT , DeeksJJ , Altman DGeditor(s) . Chapter 16: Special topics in statistics. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011c</a>). </p> </section> <section id="CD004314-sec-0060"> <h4 class="title">Dealing with missing data</h4> <p>For missing outcome or summary data we used imputation methods to derive the missing data (where possible) and reported any assumptions in the review. These cases were investigated, through sensitivity analyses, to investigate the effects of any imputed data on pooled effect estimates. </p> <p>As a first option we chose to use the available information (e.g. standard error (SE), 95% CI or exact P value) to recover the missing data algebraically (<a href="./references#CD004314-bbs2-0044" title="HigginsJP , Deeks JJeditor(s) . Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>; <a href="./references#CD004314-bbs2-0046" title="HigginsJPT , DeeksJJ , Altman DGeditor(s) . Chapter 16: Special topics in statistics. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011c</a>; <a href="./references#CD004314-bbs2-0084" title="WiebeN , VandermeerB , PlattRW , KlassenTP , MoherD , BarrowmanNJ . A systematic review identifies a lack of standardization in methods for handling missing variance data. Journal of Clinical Epidemiology2006;59(4):342‐53. ">Wiebe 2006</a>). When change from baseline SD was not reported or not possible to extract, as was the case in <a href="./references#CD004314-bbs2-0003" title="TintnerR , GrossR , WinzerUF , SmalkyKA , JankovicJ . Autonomic function after botulinum toxin type A or B: a double‐blind, randomized trial. Neurology2005;65:765‐7. ">Tintner 2005</a>, we attempted to create a correlation coefficient based on another study in this review, and then used this correlation coefficient to impute a change from baseline SD (<a href="./references#CD004314-bbs2-0004" title="AbramsKR , GilliesCL , LambertPC . Meta‐analysis of heterogeneously reported trials assessing change from baseline. Statistics in Medicine2005;24:3823‐44. ">Abrams 2005</a>; <a href="./references#CD004314-bbs2-0033" title="FollmannD , ElliottP , SuhI , CutlerJ . Variance imputation for overviews of clinical trials with continuous response. Journal of Clinical Epidemiology1992;45:769‐73. ">Follmann 1992</a>; <a href="./references#CD004314-bbs2-0046" title="HigginsJPT , DeeksJJ , Altman DGeditor(s) . Chapter 16: Special topics in statistics. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011c</a>). </p> <p>If this were to fail, and if at least one sufficiently large and similar study were to exist, we would use a method of single imputation (<a href="./references#CD004314-bbs2-0036" title="FurukawaTA , BarbuiC , CiprianiA , BrambillaP , WatanabeN . Imputing missing standard deviations in meta‐analyses can provide accurate results. Journal of Clinical Epidemiology2006;59(1):7‐10. ">Furukawa 2006</a>; <a href="./references#CD004314-bbs2-0046" title="HigginsJPT , DeeksJJ , Altman DGeditor(s) . Chapter 16: Special topics in statistics. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011c</a>). </p> <p>Lastly, if a sufficient number of included studies with complete information were to exist, we would have used multiple imputation methods to derive missing data (<a href="./references#CD004314-bbs2-0018" title="CarpenterJ , KenwardM . Multiple Imputation and its Application. Wiley, 2013. ">Carpenter 2013</a>; <a href="./references#CD004314-bbs2-0069" title="RubinDB , SchenkerN . Multiple imputation in health‐care databases: an overview and some applications. Statistics in Medicine1991;10:585–98. ">Rubin 1991</a>). </p> <p>If none of these methods were to be successful we would have conducted a narrative synthesis for the data in question. </p> </section> <section id="CD004314-sec-0061"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed that studies were similar enough to allow pooling of data using meta‐analysis. Where data was pooled using meta‐analysis, we assessed the degree of heterogeneity by visual inspection of forest plots and by examining the Chi<sup>2</sup> test for heterogeneity. We quantified heterogeneity using the I<sup>2</sup> statistic. We considered an I<sup>2</sup> value of 50% or more to represent substantial levels of heterogeneity, but interpreted this value in light of the size and direction of effects and the strength of the evidence for heterogeneity, based on the P value from the Chi<sup>2</sup> test (<a href="./references#CD004314-bbs2-0043" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557–60. ">Higgins 2003</a>). </p> </section> <section id="CD004314-sec-0062"> <h4 class="title">Assessment of reporting biases</h4> <p>We included too few studies in this review , namely fewer than 10, to allow construction of a funnel plot (<a href="./references#CD004314-bbs2-0075" title="SterneJA , EggerM . Funnel plots for detecting bias in meta‐analysis: guidelines on choice of axis. Journal of Clinical Epidemiology2001;54(10):1046‐55. ">Sterne 2001</a>), and formal testing of asymmetry (<a href="./references#CD004314-bbs2-0065" title="PetersJL , SuttonAJ , JonesDR , AbramsKR , RushtonL . Comparison of two methods to detect publication bias in meta‐analysis. JAMA2006;295(6):676‐80. ">Peters 2006</a>), which may indicate publication bias. Should enough studies be included in future updates of this review, we plan to undertake these analyses. </p> </section> <section id="CD004314-sec-0063"> <h4 class="title">Data synthesis</h4> <p>We performed the analyses with RevMan 5 version 5.3 (<a href="./references#CD004314-bbs2-0066" title="The Nordic Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>), Stata version 14 (<a href="./references#CD004314-bbs2-0073" title="StataCorp . Stata Statistical Software: release 14. Version Date accessed: September 2016. StataCorp, 2015. ">Stata 2015</a>) and TSA (<a href="./references#CD004314-bbs2-0078" title="ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . User manual for trial sequential analysis (TSA). ctu.dk/tsa/files/tsa ̇manual.pdf 2011. ">Thorlund 2011</a>; <a href="./references#CD004314-bbs2-0079" title="Copenhagen Trial Unit. Trial Sequential Analysis. Version 0.9 Beta. Version Date accessed: September 2016. Copenhagen: Copenhagen Trial Unit, 2011. ">TSA 2011</a>). </p> <section id="CD004314-sec-0064"> <h5 class="title">Meta‐analysis</h5> <p>We based the decision whether or not to meta‐analyse data on an assessment of whether the interventions in the included trials were similar enough in terms of participants, settings, intervention, comparison and outcome measures to ensure meaningful conclusions from a statistically pooled result. We conducted data synthesis using a random‐effects model. </p> <p>We pooled effect measures by applying the Mantel‐Haenszel method for dichotomous outcomes, and applying the inverse‐variance or generic inverse‐variance method for continuous outcomes. In addition, we had planned to pool time‐to‐event data using the generic inverse‐variance method. We presented all results with 95% CI. </p> <p>We calculated the number of participants needed to treat for an additional beneficial outcome (NNTB) and for an additional harmful outcome (NNTH) from meta‐analysis estimates, rather than treating data as if they came from a single trial, as the latter approach is more prone to bias, especially when there are significant imbalances between groups within one or more trials in the meta‐analysis (<a href="./references#CD004314-bbs2-0006" title="AltmanDG , DeeksJJ . Meta‐analysis, Simpson's paradox, and the number needed to treat. BMC Medical Research Methodology2002;2(1):3. ">Altman 2002</a>). However, caution is needed in the interpretation of these findings since they may be misleading because of variation in the event rates in each trial, differences in the outcomes considered, and differences in clinical setting (<a href="./references#CD004314-bbs2-0072" title="SmeethL , HainesA , EbrahimS . Numbers needed to treat derived from meta‐analysis ‐ sometimes informative, usually misleading. BMJ1999;318(7197):1548‐51. ">Smeeth 1999</a>). </p> <p>Where there were no data that could be combined into a meta‐analysis we undertook a narrative approach to result synthesis. </p> </section> <section id="CD004314-sec-0065"> <h5 class="title">Trial sequential analysis</h5> <p>In order to explore whether the cumulative data were of adequate power to evaluate the primary outcomes of this review, we performed a trial sequential analysis (<a href="./references#CD004314-bbs2-0082" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61:64‐75. ">Wetterslev 2008</a>), and calculated a required information size (also known as the <i>heterogeneity‐adjusted required information size</i>) (<a href="./references#CD004314-bbs2-0083" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in random‐effects model meta‐analyses. BMC Medical Research Methodology2009;9:86. ">Wetterslev 2009</a>). Trial sequential analysis aims to evaluate whether statistically significant results of meta‐analysis are reliable by accounting for the required information size (i.e. the number of participants in the meta‐analysis required to accept or reject an intervention effect). The technique is analogous to sequential monitoring boundaries in single trials. Trial sequential analysis adjusts the threshold of statistical significance and has been shown to reduce the risk of random errors due to repetitive testing of accumulating data (<a href="./references#CD004314-bbs2-0048" title="ImbergerG , ThorlundK , GluudC , WetterslevJ . False‐positive findings in Cochrane meta‐analyses with and without application of trial sequential analysis: an empirical review. BMJ Open2016;6(8):e011890. ">Imberger 2016</a>). </p> <p>We calculated the required information size and computed the trial sequential monitoring boundaries using the O’Brien‐Fleming approach (<a href="./references#CD004314-bbs2-0062" title="O’BrienPC , FlemingTR . A multiple testing procedure for clinical trials. Biometrics1979;35:549‐56. ">O'Brien 1979</a>). The required information size was based on the event proportion or standard deviation in the control group; assumption of a plausible relative risk reduction (RRR) of 10%; a 5% risk of type I error; a 20% risk of type II error (power = 80%); and the observed heterogeneity of the meta‐analysis (<a href="./references#CD004314-bbs2-0050" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta‐analytic methods. BMC Medical Research Methodology2014;14(1):120. ">Jakobsen 2014</a>; <a href="./references#CD004314-bbs2-0083" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in random‐effects model meta‐analyses. BMC Medical Research Methodology2009;9:86. ">Wetterslev 2009</a>). </p> </section> <section id="CD004314-sec-0066"> <h5 class="title">Assessing the quality of the evidence</h5> <p>As recommended by the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group methodology (<a href="./references#CD004314-bbs2-0070" title="SchünemannHJ , OxmanAD , HigginsJPT , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and ‘Summary of findings' tables. In: Higgins JPT, Green S editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Schünemann 2011</a>), two reviewers independently assessed all of the outcomes in the following domains: study limitations, inconsistency, indirectness, imprecision and publication bias. In case of disagreement the authors attempted to reach consensus, consulting an independent third reviewer if necessary. For this purpose, we used the GRADEprofiler (GRADEpro GDT) software tool (<a href="./references#CD004314-bbs2-0037" title="GRADE Working Group, McMaster University. GRADEpro GDT. Version Date accessed: September 2016. Hamilton (ON): GRADE Working Group, McMaster University, 2014. ">GRADEpro GDT 2014</a>), which we then used to export a 'Summary of findings' table for inclusion in the review manuscript. </p> <p>To ensure the consistency and reproducibility of GRADE judgements, we applied the following criteria to each domain for all key comparisons of the critical outcomes. </p> <p> <ul id="CD004314-list-0013"> <li> <p>Study limitations: we downgraded once if more than 30% of participants were from studies classified as being at a high risk of bias across any domain, with the exception of 'for‐profit bias'. </p> </li> <li> <p>Inconsistency: we downgraded once if heterogeneity was statistically significant or if the I<sup>2</sup> value was more than 40%. When a meta‐analysis was not performed we downgraded once if trials did not show effects in the same direction. </p> </li> <li> <p>Indirectness: we downgraded once if more than 50% of the participants were outside the target group. </p> </li> <li> <p>Imprecision: we downgraded once if the optimal information size criterion was not met or, alternatively, if it was met but the 95% CI fails to exclude important benefit or important harm (<a href="./references#CD004314-bbs2-0039" title="GuyattGH , OxmanAD , KunzR , BrozekJ , Alonso‐CoelloP , RindD , et al. GRADE guidelines 6. Rating the quality of evidence ‐ imprecision. Journal of Clinical Epidemiology2011;64(12):1283‐93. ">Guyatt 2011</a>). </p> </li> <li> <p>Publication bias: we downgraded once where there was direct evidence of publication bias or if estimates of effect based on small scale, industry‐sponsored studies raised a high index of suspicion of publication bias. </p> </li> </ul> </p> <p>We applied the following definitions to the quality of evidence (<a href="./references#CD004314-bbs2-0009" title="BalshemH , HelfandM , SchünemannHJ , OxmanAD , KunzR , BrozekJ , et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology2011;64(4):401‐6. ">Balshem 2011</a>): </p> <p> <ul id="CD004314-list-0014"> <li> <p>high quality: we are very confident that the true effect lies close to that of the estimate of the effect; </p> </li> <li> <p>moderate quality: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different; </p> </li> <li> <p>low quality: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect; </p> </li> <li> <p>very low quality: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </li> </ul> </p> </section> <section id="CD004314-sec-0067"> <h5 class="title">'Summary of findings' table</h5> <p>As has become standard practice in Cochrane Reviews, we have included a 'Summary of findings' table to present the main findings of this review in a simple tabular format, based on the results of the GRADE analysis. In particular, we included key information concerning the quality of evidence, the magnitude of effect of the interventions examined, and the sum of available data on the outcome overall cervical dystonia improvement, proportion of participants with adverse events, subjective change as assessed by the patient, cervical dystonia associated pain, sore throat/dry mouth, and dysphagia (difficulty swallowing). </p> </section> </section> <section id="CD004314-sec-0068"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to conduct subgroup analyses according to the dosages of Bt used, though this was not possible given the paucity of results. In particular, we included key information concerning the quality of evidence, the magnitude of effect of the interventions examined, and the sum of the available data on the outcome. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD004314-sec-0069" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD004314-sec-0069"></div> <section id="CD004314-sec-0070"> <h3 class="title">Description of studies</h3> <p>We identified three new studies for inclusion in this update: <a href="./references#CD004314-bbs2-0001" title="ComellaCL , JankovicJ , ShannonKM , TsuiJ , SwensonM , LeurgansS , et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology2005;65:1423‐9. [DOI: 10.1212/01.wnl.0000183055.81056.5c] ">Comella 2005</a>; <a href="./references#CD004314-bbs2-0002" title="PappertEJ , GermansonT . Botulinum toxin type B vs. type A in toxin‐naïve patients with cervical dystonia: randomized double‐blind, noninferiority trial. Movement Disorders2008;23:510‐7. ">Pappert 2008</a>; <a href="./references#CD004314-bbs2-0003" title="TintnerR , GrossR , WinzerUF , SmalkyKA , JankovicJ . Autonomic function after botulinum toxin type A or B: a double‐blind, randomized trial. Neurology2005;65:765‐7. ">Tintner 2005</a>. </p> <section id="CD004314-sec-0071"> <h4 class="title">Results of the search</h4> <p>See: <a href="#CD004314-fig-0001">Figure 1</a>, flow diagram of study selection. </p> <p>We last ran the electronic search in October 2016. The search returned 1646 records (208 through CENTRAL; 182 though MEDLINE; 1256 through Embase), resulting in 1599 records after removing all duplicates. After title and abstract screening, three articles were assessed for full‐text screening, with all three being included for both the qualitative and quantitative syntheses. We did not retrieve any unpublished trials. </p> </section> <section id="CD004314-sec-0072"> <h4 class="title">Included studies</h4> <p>We have listed all the included studies in this review in the '<a href="./references#CD004314-sec-0118" title="">Characteristics of included studies</a>' table. </p> <p>The three studies included in this review are parallel‐group RCTs comparing BtA and BtB for adults (i.e. 18 years of age or over) with cervical dystonia. Trial size varied from 20 to 139 participants. Two of the included RCTs were multi‐centre studies conducted in North America and Europe (<a href="./references#CD004314-bbs2-0001" title="ComellaCL , JankovicJ , ShannonKM , TsuiJ , SwensonM , LeurgansS , et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology2005;65:1423‐9. [DOI: 10.1212/01.wnl.0000183055.81056.5c] ">Comella 2005</a>; <a href="./references#CD004314-bbs2-0002" title="PappertEJ , GermansonT . Botulinum toxin type B vs. type A in toxin‐naïve patients with cervical dystonia: randomized double‐blind, noninferiority trial. Movement Disorders2008;23:510‐7. ">Pappert 2008</a>), while the remaining trial was a single‐centred study conducted in the USA (<a href="./references#CD004314-bbs2-0003" title="TintnerR , GrossR , WinzerUF , SmalkyKA , JankovicJ . Autonomic function after botulinum toxin type A or B: a double‐blind, randomized trial. Neurology2005;65:765‐7. ">Tintner 2005</a>). All trials were conducted in the 2000s. </p> <p>Overall, 270 participants were enrolled, 171 of whom were female (63.3%). A total of 141 participants included in this review were randomised to the BtA arm of their respective studies, with the remaining 129 participants randomised to the BtB arm. The average age of participants among the three trials was 53.3 years. The baseline mean cervical dystonia symptoms were moderate to severe in all participants, and well matched between study arms, with baseline TWSTRS total scores of 41.8 and 45.6 for participants in <a href="./references#CD004314-bbs2-0001" title="ComellaCL , JankovicJ , ShannonKM , TsuiJ , SwensonM , LeurgansS , et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology2005;65:1423‐9. [DOI: 10.1212/01.wnl.0000183055.81056.5c] ">Comella 2005</a> and <a href="./references#CD004314-bbs2-0002" title="PappertEJ , GermansonT . Botulinum toxin type B vs. type A in toxin‐naïve patients with cervical dystonia: randomized double‐blind, noninferiority trial. Movement Disorders2008;23:510‐7. ">Pappert 2008</a>, respectively, which may be interpreted as representing a moderate overall disease impairment. <a href="./references#CD004314-bbs2-0003" title="TintnerR , GrossR , WinzerUF , SmalkyKA , JankovicJ . Autonomic function after botulinum toxin type A or B: a double‐blind, randomized trial. Neurology2005;65:765‐7. ">Tintner 2005</a> did not provide data for baseline TWSTRS total score. The mean duration of cervical dystonia was 7.9 years and 6.6 years for participants in <a href="./references#CD004314-bbs2-0001" title="ComellaCL , JankovicJ , ShannonKM , TsuiJ , SwensonM , LeurgansS , et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology2005;65:1423‐9. [DOI: 10.1212/01.wnl.0000183055.81056.5c] ">Comella 2005</a> and <a href="./references#CD004314-bbs2-0002" title="PappertEJ , GermansonT . Botulinum toxin type B vs. type A in toxin‐naïve patients with cervical dystonia: randomized double‐blind, noninferiority trial. Movement Disorders2008;23:510‐7. ">Pappert 2008</a>, respectively. <a href="./references#CD004314-bbs2-0003" title="TintnerR , GrossR , WinzerUF , SmalkyKA , JankovicJ . Autonomic function after botulinum toxin type A or B: a double‐blind, randomized trial. Neurology2005;65:765‐7. ">Tintner 2005</a> did not provide data for the number of years since diagnosis of dystonia. <a href="./references#CD004314-bbs2-0002" title="PappertEJ , GermansonT . Botulinum toxin type B vs. type A in toxin‐naïve patients with cervical dystonia: randomized double‐blind, noninferiority trial. Movement Disorders2008;23:510‐7. ">Pappert 2008</a> enrolled exclusively Bt‐naive participants (no prior exposure to any form of Bt), while the remaining studies enrolled participants with a known positive response to BtA exclusively (<a href="./references#CD004314-bbs2-0001" title="ComellaCL , JankovicJ , ShannonKM , TsuiJ , SwensonM , LeurgansS , et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology2005;65:1423‐9. [DOI: 10.1212/01.wnl.0000183055.81056.5c] ">Comella 2005</a>; <a href="./references#CD004314-bbs2-0003" title="TintnerR , GrossR , WinzerUF , SmalkyKA , JankovicJ . Autonomic function after botulinum toxin type A or B: a double‐blind, randomized trial. Neurology2005;65:765‐7. ">Tintner 2005</a>). Overall, 58.9% of the participants included in this review had a known positive response to BtA. None of the included trials described the method of participant referral and recruitment prior to study enrolment. Within each study, as well as when considered together, participants were well matched for clinical and demographic characteristics between BtA and BtB arms at baseline. </p> <p>All studies were designed to evaluate only a single treatment session. Two studies used doses from 100 U to 250 U of BtA ‐ both onabotulinumtoxinA formulations ‐ and 5000 U to 10,000 U of BtB (<a href="./references#CD004314-bbs2-0001" title="ComellaCL , JankovicJ , ShannonKM , TsuiJ , SwensonM , LeurgansS , et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology2005;65:1423‐9. [DOI: 10.1212/01.wnl.0000183055.81056.5c] ">Comella 2005</a>; <a href="./references#CD004314-bbs2-0002" title="PappertEJ , GermansonT . Botulinum toxin type B vs. type A in toxin‐naïve patients with cervical dystonia: randomized double‐blind, noninferiority trial. Movement Disorders2008;23:510‐7. ">Pappert 2008</a>), while the remaining study referred only to botulinum doses being administered at a 1:50 ratio of BtA (onabotulinumtoxinA formulation) to BtB (<a href="./references#CD004314-bbs2-0003" title="TintnerR , GrossR , WinzerUF , SmalkyKA , JankovicJ . Autonomic function after botulinum toxin type A or B: a double‐blind, randomized trial. Neurology2005;65:765‐7. ">Tintner 2005</a>). In all studies, and within these limits, the Bt doses administered were left at the discretion of the clinician. Techniques and schema of Bt administration did not vary a great deal among studies. In all trials, the toxin was injected into the muscles involved in cervical dystonia selected by the investigator, with the use of electromyography left to the discretion of the clinician performing the injection. </p> <p><a href="./references#CD004314-bbs2-0001" title="ComellaCL , JankovicJ , ShannonKM , TsuiJ , SwensonM , LeurgansS , et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology2005;65:1423‐9. [DOI: 10.1212/01.wnl.0000183055.81056.5c] ">Comella 2005</a> and <a href="./references#CD004314-bbs2-0002" title="PappertEJ , GermansonT . Botulinum toxin type B vs. type A in toxin‐naïve patients with cervical dystonia: randomized double‐blind, noninferiority trial. Movement Disorders2008;23:510‐7. ">Pappert 2008</a> both used TWSTRS total score at week 4 post‐injection as the primary efficacy outcome. <a href="./references#CD004314-bbs2-0003" title="TintnerR , GrossR , WinzerUF , SmalkyKA , JankovicJ . Autonomic function after botulinum toxin type A or B: a double‐blind, randomized trial. Neurology2005;65:765‐7. ">Tintner 2005</a> was designed with the specific objective of comparing the autonomic effects of Bt, reporting only TWSTRS sub‐scores at baseline and at week 3 post‐injection. <a href="./references#CD004314-bbs2-0001" title="ComellaCL , JankovicJ , ShannonKM , TsuiJ , SwensonM , LeurgansS , et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology2005;65:1423‐9. [DOI: 10.1212/01.wnl.0000183055.81056.5c] ">Comella 2005</a> and <a href="./references#CD004314-bbs2-0002" title="PappertEJ , GermansonT . Botulinum toxin type B vs. type A in toxin‐naïve patients with cervical dystonia: randomized double‐blind, noninferiority trial. Movement Disorders2008;23:510‐7. ">Pappert 2008</a> also studied subjective response as assessed by participants and clinicians. Regarding safety outcomes, all studies reported treatment‐associated adverse events. <a href="./references#CD004314-bbs2-0001" title="ComellaCL , JankovicJ , ShannonKM , TsuiJ , SwensonM , LeurgansS , et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology2005;65:1423‐9. [DOI: 10.1212/01.wnl.0000183055.81056.5c] ">Comella 2005</a> reported data using an intention‐to‐treat (ITT) principle. One study specified the method of data analysis used (<a href="./references#CD004314-bbs2-0002" title="PappertEJ , GermansonT . Botulinum toxin type B vs. type A in toxin‐naïve patients with cervical dystonia: randomized double‐blind, noninferiority trial. Movement Disorders2008;23:510‐7. ">Pappert 2008</a>), stating that data was analysed using both per‐protocol (PP) and ITT principles. However, only PP data were reported, with the claim by the authors that no difference existed between PP and ITT results. None of the included trials had an available protocol register. </p> <p>All trials were short‐term, with a follow‐up period lasting 16 to 20 weeks post‐injection or until such time as reinjection was required. </p> </section> <section id="CD004314-sec-0073"> <h4 class="title">Excluded studies</h4> <p>All reports that were entered for full‐text screening were assessed as eligible for inclusion in this review. </p> </section> </section> <section id="CD004314-sec-0074"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="./references#CD004314-sec-0118" title="">Characteristics of included studies</a>: 'Risk of bias' table. </p> <p>The included studies were evaluated using a modified version of the Cochrane 'Risk of bias' tool. See <a href="#CD004314-fig-0002">Figure 2</a> and <a href="#CD004314-fig-0003">Figure 3</a> for the 'Risk of bias' summary graphs. These assessments were based on the information available in the primary report data. </p> <div class="figure" id="CD004314-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD004314-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/image_n/nCD004314-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD004314-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD004314-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/image_n/nCD004314-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <p>We considered that none of the included studies had a high risk of bias in all domains, though we rated the 'for‐profit bias' domain at a high risk of bias in all studies, and considered the 'selective reporting' domain at a high risk of bias in one study (<a href="./references#CD004314-bbs2-0003" title="TintnerR , GrossR , WinzerUF , SmalkyKA , JankovicJ . Autonomic function after botulinum toxin type A or B: a double‐blind, randomized trial. Neurology2005;65:765‐7. ">Tintner 2005</a>). We additionally rated all studies to as having a low risk of bias with regard to the incomplete outcome data domain. </p> <section id="CD004314-sec-0075"> <h4 class="title">Allocation</h4> <p><a href="./references#CD004314-bbs2-0001" title="ComellaCL , JankovicJ , ShannonKM , TsuiJ , SwensonM , LeurgansS , et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology2005;65:1423‐9. [DOI: 10.1212/01.wnl.0000183055.81056.5c] ">Comella 2005</a> adequately described the method of randomisation (permuted block allocation scheme), though made no specific description of allocation concealment. We chose to rate <a href="./references#CD004314-bbs2-0001" title="ComellaCL , JankovicJ , ShannonKM , TsuiJ , SwensonM , LeurgansS , et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology2005;65:1423‐9. [DOI: 10.1212/01.wnl.0000183055.81056.5c] ">Comella 2005</a> as having a low risk of selection bias. We considered that the remaining studies had an unclear risk of bias (<a href="./references#CD004314-bbs2-0002" title="PappertEJ , GermansonT . Botulinum toxin type B vs. type A in toxin‐naïve patients with cervical dystonia: randomized double‐blind, noninferiority trial. Movement Disorders2008;23:510‐7. ">Pappert 2008</a>; <a href="./references#CD004314-bbs2-0003" title="TintnerR , GrossR , WinzerUF , SmalkyKA , JankovicJ . Autonomic function after botulinum toxin type A or B: a double‐blind, randomized trial. Neurology2005;65:765‐7. ">Tintner 2005</a>), as no specific and reproducible descriptions were made regarding the methods of randomisation and allocation concealment. </p> </section> <section id="CD004314-sec-0076"> <h4 class="title">Blinding</h4> <p>Two studies adequately reported the methods of guaranteeing blinding, being correctly executed, double‐blind controlled trials, so we rated them as having a low risk of bias (<a href="./references#CD004314-bbs2-0001" title="ComellaCL , JankovicJ , ShannonKM , TsuiJ , SwensonM , LeurgansS , et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology2005;65:1423‐9. [DOI: 10.1212/01.wnl.0000183055.81056.5c] ">Comella 2005</a>; <a href="./references#CD004314-bbs2-0002" title="PappertEJ , GermansonT . Botulinum toxin type B vs. type A in toxin‐naïve patients with cervical dystonia: randomized double‐blind, noninferiority trial. Movement Disorders2008;23:510‐7. ">Pappert 2008</a>). We rated the remaining study as having an unclear risk of bias (<a href="./references#CD004314-bbs2-0003" title="TintnerR , GrossR , WinzerUF , SmalkyKA , JankovicJ . Autonomic function after botulinum toxin type A or B: a double‐blind, randomized trial. Neurology2005;65:765‐7. ">Tintner 2005</a>). </p> </section> <section id="CD004314-sec-0077"> <h4 class="title">Incomplete outcome data</h4> <p>Two studies adequately reported the number and reasons for participant exclusions in both treatment arms (<a href="./references#CD004314-bbs2-0001" title="ComellaCL , JankovicJ , ShannonKM , TsuiJ , SwensonM , LeurgansS , et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology2005;65:1423‐9. [DOI: 10.1212/01.wnl.0000183055.81056.5c] ">Comella 2005</a>; <a href="./references#CD004314-bbs2-0003" title="TintnerR , GrossR , WinzerUF , SmalkyKA , JankovicJ . Autonomic function after botulinum toxin type A or B: a double‐blind, randomized trial. Neurology2005;65:765‐7. ">Tintner 2005</a>), these were evenly distributed across both treatment arms, and so we rated them as having a low risk of bias. <a href="./references#CD004314-bbs2-0002" title="PappertEJ , GermansonT . Botulinum toxin type B vs. type A in toxin‐naïve patients with cervical dystonia: randomized double‐blind, noninferiority trial. Movement Disorders2008;23:510‐7. ">Pappert 2008</a> did not provide data according to an ITT principle, so we chose to grade this study as being at an uncertain risk of attrition bias. </p> </section> <section id="CD004314-sec-0078"> <h4 class="title">Selective reporting</h4> <p>We considered that the more clinically relevant outcomes that are usually evaluated in intervention trials for this condition were reported in both <a href="./references#CD004314-bbs2-0001" title="ComellaCL , JankovicJ , ShannonKM , TsuiJ , SwensonM , LeurgansS , et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology2005;65:1423‐9. [DOI: 10.1212/01.wnl.0000183055.81056.5c] ">Comella 2005</a> and <a href="./references#CD004314-bbs2-0002" title="PappertEJ , GermansonT . Botulinum toxin type B vs. type A in toxin‐naïve patients with cervical dystonia: randomized double‐blind, noninferiority trial. Movement Disorders2008;23:510‐7. ">Pappert 2008</a>, which is why they were considered to be at low risk of bias for reporting data. We rated the remaining study as having a high risk of bias for this domain (<a href="./references#CD004314-bbs2-0003" title="TintnerR , GrossR , WinzerUF , SmalkyKA , JankovicJ . Autonomic function after botulinum toxin type A or B: a double‐blind, randomized trial. Neurology2005;65:765‐7. ">Tintner 2005</a>). This is because it referred in the methods section to having selected several outcomes, though only two of these were reported in the results. Additionally, none of the included studies had a registered trial protocol available. </p> </section> <section id="CD004314-sec-0079"> <h4 class="title">Other potential sources of bias</h4> <section id="CD004314-sec-0080"> <h5 class="title">For‐profit bias</h5> <p>All studies were supported, wholly or in part, by pharmaceutical companies (Allergan, Inc and Soltice Neurosciences, Inc) (<a href="./references#CD004314-bbs2-0001" title="ComellaCL , JankovicJ , ShannonKM , TsuiJ , SwensonM , LeurgansS , et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology2005;65:1423‐9. [DOI: 10.1212/01.wnl.0000183055.81056.5c] ">Comella 2005</a>; <a href="./references#CD004314-bbs2-0002" title="PappertEJ , GermansonT . Botulinum toxin type B vs. type A in toxin‐naïve patients with cervical dystonia: randomized double‐blind, noninferiority trial. Movement Disorders2008;23:510‐7. ">Pappert 2008</a>; <a href="./references#CD004314-bbs2-0003" title="TintnerR , GrossR , WinzerUF , SmalkyKA , JankovicJ . Autonomic function after botulinum toxin type A or B: a double‐blind, randomized trial. Neurology2005;65:765‐7. ">Tintner 2005</a>). </p> </section> <section id="CD004314-sec-0081"> <h5 class="title">Enriched population</h5> <p>We believe that all included studies potentially had a form of enriched population. Two studies exclusively enrolled positive responders to treatment with BtA (<a href="./references#CD004314-bbs2-0001" title="ComellaCL , JankovicJ , ShannonKM , TsuiJ , SwensonM , LeurgansS , et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology2005;65:1423‐9. [DOI: 10.1212/01.wnl.0000183055.81056.5c] ">Comella 2005</a>; <a href="./references#CD004314-bbs2-0003" title="TintnerR , GrossR , WinzerUF , SmalkyKA , JankovicJ . Autonomic function after botulinum toxin type A or B: a double‐blind, randomized trial. Neurology2005;65:765‐7. ">Tintner 2005</a>), meaning that there was a potential risk of population enrichment in 159 of the 270 participants (59%) included in this review. These two studies also excluded people known to have poorer responses to treatment with botulinum toxin (<a href="./references#CD004314-bbs2-0001" title="ComellaCL , JankovicJ , ShannonKM , TsuiJ , SwensonM , LeurgansS , et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology2005;65:1423‐9. [DOI: 10.1212/01.wnl.0000183055.81056.5c] ">Comella 2005</a>; <a href="./references#CD004314-bbs2-0002" title="PappertEJ , GermansonT . Botulinum toxin type B vs. type A in toxin‐naïve patients with cervical dystonia: randomized double‐blind, noninferiority trial. Movement Disorders2008;23:510‐7. ">Pappert 2008</a>), namely people with pure anterocollis and retrocollis. </p> </section> <section id="CD004314-sec-0082"> <h5 class="title">Publication bias</h5> <p>We intended to use funnel plots to explore publication bias. However, due to the small number of included studies, the power of this analysis was considered to be inadequate (<a href="./references#CD004314-bbs2-0076" title="SterneJAC , EggerM , MoherD editor(s) . Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Sterne 2011</a>). </p> </section> </section> </section> <section id="CD004314-sec-0083"> <h3 class="title" id="CD004314-sec-0083">Effects of interventions</h3> <p>See: <a href="./full#CD004314-tbl-0001"><b>Summary of findings for the main comparison</b> Botulinum toxin type A versus botulinum toxin type B for adults with cervical dystonia</a> </p> <p>The key results of this review can be found in ‘<a href="./full#CD004314-tbl-0001">summary of findings Table for the main comparison</a>’. </p> <section id="CD004314-sec-0084"> <h4 class="title">Preceding data analysis</h4> <p>See <a href="#CD004314-sec-0060">Dealing with missing data</a>. </p> <p>In this review we derived the values of the change from baseline SD for each of the TWSTRS sub‐scales (pain, severity and disability) in <a href="./references#CD004314-bbs2-0003" title="TintnerR , GrossR , WinzerUF , SmalkyKA , JankovicJ . Autonomic function after botulinum toxin type A or B: a double‐blind, randomized trial. Neurology2005;65:765‐7. ">Tintner 2005</a>. In this case we created a correlation coefficient for each sub‐scale based on <a href="https://archie.cochrane.org/sections/documents/view?version=z1603290105300954794594189801078%26format=REVMAN#STD-Pappert-2008" target="_blank">Pappert 2008</a>, and then used this to impute the change from baseline SD for each sub‐scale, for both BtA and BtB. Since <a href="https://archie.cochrane.org/sections/documents/view?version=z1603290105300954794594189801078%26format=REVMAN#STD-Pappert-2008" target="_blank">Pappert 2008</a> did not report the final SD for each intervention group we opted to substitute it with the baseline SD, as it is reasonable to assume that the intervention does not alter the variability of the outcome measure (<a href="./references#CD004314-bbs2-0046" title="HigginsJPT , DeeksJJ , Altman DGeditor(s) . Chapter 16: Special topics in statistics. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011c</a>). In all cases the correlation coefficient was greater than 0.5, which provides added security to our imputation. </p> <p>We had no further need to use imputation methods.</p> <p>We conducted sensitivity analyses for each case in which imputation methods were applied.</p> </section> <section id="CD004314-sec-0085"> <h4 class="title">Primary outcomes</h4> <section id="CD004314-sec-0086"> <h5 class="title">Overall improvement on any validated symptomatic rating scale for cervical dystonia</h5> <p>The Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) is currently the most common clinical validated tool to assess and document the status of people with cervical dystonia (<a href="./references#CD004314-bbs2-0022" title="ConskyES , LangAE . Clinical assessments of patients with cervical dystonia. In: JankovicJ , HallettM editor(s). Therapy with Botulinum Toxin. New York (NY): Marcel Dekker, Inc, 1994:211‐37. ">Consky 1994</a>). The TWSTRS (total score range, 0 to 85) is composite of three sub‐scales that evaluate different features of cervical dystonia, namely severity (range, 0 to 35), disability (range, 0 to 30) and pain (range, 0 to 20). The higher the score, the greater the level of morbidity. In the absence of a validated value for a clinically meaningful change in TWSTRS total score, we have considered a 10% change from participants' baseline status as representing a clinically meaningful change. </p> <p>Two studies (n = 231) reported data for the mean change from baseline in TWSTRS total score (<a href="https://archie.cochrane.org/sections/documents/view?version=z1603290105300954794594189801078%26format=REVMAN#STD-Comella-2005" target="_blank">Comella 2005</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z1603290105300954794594189801078%26format=REVMAN#STD-Pappert-2008" target="_blank">Pappert 2008</a>), with no difference between the BtA and BtB treatment groups, mean difference (MD) ‐1.44 (95% CI ‐3.58 to 0.70; I<sup>2</sup> = 0%; <a href="./references#CD004314-fig-0005" title="">Analysis 1.1</a>; <a href="#CD004314-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD004314-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Botulinum toxin type A versus botulinum toxin type B, outcome: 1.1 Overall cervical dystonia improvement as assessed with validated scales: change from baseline to week 4." data-id="CD004314-fig-0004" src="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/image_n/nCD004314-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Botulinum toxin type A versus botulinum toxin type B, outcome: 1.1 Overall cervical dystonia improvement as assessed with validated scales: change from baseline to week 4. </p> </div> </div> </div> <p>In relation to the trial sequential analysis, the cumulative evidence overcame the information size generated by a conventional sample size calculation, assuming a baseline TWSTRS of 40 points and a required change of 10% from baseline, with an SD of 8.3. The cumulative evidence also overcame the heterogeneity‐adjusted required information size of 138 participants. </p> <p>We were able to use data from all three included studies to calculate the improvement on TWSTRS sub‐scales, with there being no difference between the BtA and BtB groups with regard to both TWSTRS severity (MD ‐0.26; 95% CI ‐1.27 to 0.75; I<sup>2</sup> = 0%; <a href="./references#CD004314-fig-0006" title="">Analysis 1.2</a>) and TWSTRS disability (MD ‐0.17; 95% CI ‐1.19 to 0.86; I<sup>2</sup> = 0%; <a href="./references#CD004314-fig-0007" title="">Analysis 1.3</a>). </p> </section> <section id="CD004314-sec-0087"> <h5 class="title">Proportion of participants with adverse events</h5> <p>One study (n = 111) reported data concerning the proportion of participants with adverse events (<a href="https://archie.cochrane.org/sections/documents/view?version=z1603290105300954794594189801078%26format=REVMAN#STD-Pappert-2008" target="_blank">Pappert 2008</a>). In this study BtA and BtB treatment were not associated with different risks for adverse events (RR 1.40; 95% CI 1.00 to 1.96; <a href="./references#CD004314-fig-0008" title="">Analysis 1.4</a>). </p> <p>We were not able to calculate a heterogeneity‐adjusted required information size for this outcome since it was only reported in one study. However, the total number of participants included in this trial was less than the number generated by a conventional sample size calculation for a single adequately powered equivalence trial. Therefore, the cumulative evidence was not adequately powered for evaluation of the proportion of participants with adverse events. </p> </section> </section> <section id="CD004314-sec-0088"> <h4 class="title">Secondary outcomes</h4> <section id="CD004314-sec-0089"> <h5 class="title">Change in subjective evaluation of clinical status evaluated both by patients and clinicians </h5> <p>One study (138 participants) reported data with regard to subjective assessments by both clinicians and patients at week 4 after treatment. (<a href="./references#CD004314-bbs2-0001" title="ComellaCL , JankovicJ , ShannonKM , TsuiJ , SwensonM , LeurgansS , et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology2005;65:1423‐9. [DOI: 10.1212/01.wnl.0000183055.81056.5c] ">Comella 2005</a>) The instruments used to measure this outcome were the Patient Global Assessment (PGA) and Subjective Global Assessment (SGA) scales. The PGA and SGA ratings ranged from ‐4 (marked worsening of cervical dystonia signs) to 4 (complete abolishment of cervical dystonia signs). </p> <p>Both forms of subjective assessment, measured as mean change from baseline in PGA and SGA, were not different between BtA and BtB groups, (PGA MD 0.20; 95% CI ‐0.17 to 0.57; <a href="./references#CD004314-fig-0009" title="">Analysis 1.5</a>; SGA MD 0.20; 95% CI ‐0.20 to 0.60; <a href="./references#CD004314-fig-0010" title="">Analysis 1.6</a>). </p> <p><a href="./references#CD004314-bbs2-0002" title="PappertEJ , GermansonT . Botulinum toxin type B vs. type A in toxin‐naïve patients with cervical dystonia: randomized double‐blind, noninferiority trial. Movement Disorders2008;23:510‐7. ">Pappert 2008</a> also mentioned having studied subjective evaluation of clinical status by both patients and clinicians, though the final report did not include any data for this analysis, referring only to the fact that all evaluations were similar between treatment arms. </p> </section> <section id="CD004314-sec-0090"> <h5 class="title">Changes in pain scores, as assessed with validated assessment tools</h5> <p>All included trials provided data in the form of mean change from baseline on TWSTRS pain sub‐scale (range, 0 to 20); there was no difference between the intervention groups for this outcome (MD ‐0.83; 95% CI ‐1.75 to 0.09; I<sup>2</sup> = 0%; <a href="./references#CD004314-fig-0011" title="">Analysis 1.7</a>). </p> </section> <section id="CD004314-sec-0091"> <h5 class="title">Changes in quality of life assessments</h5> <p>None of the included trials studied the effect of BtA or BtB on the quality of life of people with cervical dystonia. </p> </section> <section id="CD004314-sec-0092"> <h5 class="title">Proportion of participants with adverse events of special interest</h5> <p>The most frequently reported adverse events were sore throat/dry mouth (24.5%) (<a href="./references#CD004314-bbs2-0001" title="ComellaCL , JankovicJ , ShannonKM , TsuiJ , SwensonM , LeurgansS , et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology2005;65:1423‐9. [DOI: 10.1212/01.wnl.0000183055.81056.5c] ">Comella 2005</a>; <a href="./references#CD004314-bbs2-0002" title="PappertEJ , GermansonT . Botulinum toxin type B vs. type A in toxin‐naïve patients with cervical dystonia: randomized double‐blind, noninferiority trial. Movement Disorders2008;23:510‐7. ">Pappert 2008</a>), and dysphagia (18.2%) (<a href="./references#CD004314-bbs2-0001" title="ComellaCL , JankovicJ , ShannonKM , TsuiJ , SwensonM , LeurgansS , et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology2005;65:1423‐9. [DOI: 10.1212/01.wnl.0000183055.81056.5c] ">Comella 2005</a>; <a href="./references#CD004314-bbs2-0002" title="PappertEJ , GermansonT . Botulinum toxin type B vs. type A in toxin‐naïve patients with cervical dystonia: randomized double‐blind, noninferiority trial. Movement Disorders2008;23:510‐7. ">Pappert 2008</a>; <a href="./references#CD004314-bbs2-0003" title="TintnerR , GrossR , WinzerUF , SmalkyKA , JankovicJ . Autonomic function after botulinum toxin type A or B: a double‐blind, randomized trial. Neurology2005;65:765‐7. ">Tintner 2005</a>). Dysphagia was equally likely in BtA and BtB‐treated participants (RR 2.89; 95% CI 0.80 to 10.41; I<sup>2</sup>=74%; <a href="./references#CD004314-fig-0013" title="">Analysis 1.9</a>). Sore throat/dry mouth was more likely among BtB‐treated participants in comparison to BtA‐treated ones, with a RR of 4.39 (95% CI 2.43 to 7.91; I<sup>2</sup>=0%; <a href="./references#CD004314-fig-0012" title="">Analysis 1.8</a>). The NNTH in BtB‐treated participants compared to BtA‐treated participants for sore throat/dry mouth was 3 (95% CI 4 to 2). </p> <p>For all other reported adverse events, including pain at injection site, no difference was found between groups. </p> </section> <section id="CD004314-sec-0093"> <h5 class="title">Duration of effect, or number of days until need for reinjection or effect waning</h5> <p>This item was reported in two studies (n = 231) (<a href="./references#CD004314-bbs2-0001" title="ComellaCL , JankovicJ , ShannonKM , TsuiJ , SwensonM , LeurgansS , et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology2005;65:1423‐9. [DOI: 10.1212/01.wnl.0000183055.81056.5c] ">Comella 2005</a>; <a href="./references#CD004314-bbs2-0002" title="PappertEJ , GermansonT . Botulinum toxin type B vs. type A in toxin‐naïve patients with cervical dystonia: randomized double‐blind, noninferiority trial. Movement Disorders2008;23:510‐7. ">Pappert 2008</a>), though we opted not to combine the data through a quantitative synthesis (meta‐analysis) due to this outcome being reported as survival time for the median of each arm with the inherent limitations that entails (<a href="./references#CD004314-bbs2-0060" title="MichielsS , PiedboisP , BurdettS , SyzN , StewartL , PignonJP . Meta‐analysis when only the median survival times are known: a comparison with individual patient data results. International Journal of Technology Assessment in Health Care2005;21(1):119‐25. ">Michiels 2005</a>). </p> <p><a href="./references#CD004314-bbs2-0002" title="PappertEJ , GermansonT . Botulinum toxin type B vs. type A in toxin‐naïve patients with cervical dystonia: randomized double‐blind, noninferiority trial. Movement Disorders2008;23:510‐7. ">Pappert 2008</a> reported that among its 93 participants both formulations of Bt did not differ from one another ‐ median treatment duration of effect was 13.1 weeks in the BtA arm and 13.7 weeks in the BtB arm (hazard ratio (HR) 0.95; 95% CI 0.56 to 1.59; log rank P = 0.833). The trialists performed a subgroup analysis for participants who showed an improvement from baseline at week 4 (n = 83) was also conducted, without a difference between the groups (HR 0.79; 95% CI 0.45 to 1.41; log rank P = 0.414). </p> <p>Similarly, <a href="./references#CD004314-bbs2-0001" title="ComellaCL , JankovicJ , ShannonKM , TsuiJ , SwensonM , LeurgansS , et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology2005;65:1423‐9. [DOI: 10.1212/01.wnl.0000183055.81056.5c] ">Comella 2005</a> reported that among its 138 participants both formulations of Bt did not differ from one another ‐ median treatment duration of effect was 13.0 weeks in the BtA arm and 11.7 weeks in the BtB arm (HR 95% CI 0.55 to 1.07). A subgroup analysis for participants who showed an improvement from baseline at week 4 was also conducted, with a median time to loss of benefit of 14 weeks for BtA and 12.1 weeks for BtB. The trialists presented the results of a log rank test for this subgroup reporting a difference in the two distributions (HR 95% CI 0.43 to 0.98). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD004314-sec-0094" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004314-sec-0094">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004314-sec-0135">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD004314-sec-0094"></div> <section id="CD004314-sec-0095"> <h3 class="title" id="CD004314-sec-0095">Summary of main results</h3> <p>This updated review included three randomised, parallel‐designed trials, that enrolled 270 participants with cervical dystonia, of whom 62.3% had been previously treated with botulinum toxin type A (BtA). As can be seen in the <a href="./full#CD004314-tbl-0001">summary of findings Table for the main comparison</a>, BtA (onabotulinumtoxinA) and botulinum toxin type B (BtB; rimabotulinumtoxinB) were equally effective in reducing overall disease impairment, including disease severity, disability, and pain. Subjective assessments by both participants and clinicians were likewise not different between BtA and BtB. The comparative impacts of both forms of botulinum toxin on other domains of participants’ quality of life, such as social functioning or mental health, have not been addressed in the included trials. </p> <p>Overall adverse event rates were not different between groups, though this may be due to the small sample that was analysed for this outcome. The short duration of the trials, as well as the reduced sample size, precluded the drawing of strong conclusions regarding the lack of differences between BtA and BtB. The most common adverse events of special interest related to treatment were sore throat/dry mouth and dysphagia. Of these, only the risk of sore throat/dry mouth was different between the treatment groups, with BtB‐treated participants experiencing an increased risk of this adverse event, with a number needed to treat for one additional harmful event of 3 after a single botulinum toxin (Bt) injection. No fatalities or serious adverse events were considered to be related to either treatment in any of the trials. Data for special subpopulations, such as people with certain types of cervical dystonia known to respond poorly to Bt treatment, as well as for children and pregnant women, were not available. </p> <p>We found low‐to‐moderate statistical heterogeneity for most efficacy and safety outcome estimates, the exception being dysphagia. </p> </section> <section id="CD004314-sec-0096"> <h3 class="title" id="CD004314-sec-0096">Overall completeness and applicability of evidence</h3> <p>All included trials addressed the primary research question directly, using the same assessment tool, the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS). However, data were not fully reported for all outcomes, and in some cases results could not be pooled and compared across studies. This limited the amount of data available and, consequently, our confidence in the overall conclusions. </p> <p>The participants included in the studies were not fully representative of the overall population of people with cervical dystonia. The effects of population enrichment and the moderate overall disease impairment (as assessed by the baseline TWSTRS scores) preclude definite conclusions concerning all people with this condition. </p> <p>Since the included trials use only onabotulinumtoxinA, there are no data regarding the efficacy and safety profile of BtB versus other forms of BtA, namely abobotulinumtoxinA and incobotulinumtoxinA. </p> <p>Four noteworthy factors challenge the implementation of the evidence derived from this review. Firstly, a limited number of centres conducted the research, and these were heterogeneous in terms of their regional distribution, with all trials being conducted in Europe or North America. Differences in clinical practice, training of experts, and local guidelines in other regions of the world may conceivably present an obstacle to application of the evidence summarised here. Secondly, the total number of participants across several outcomes was less than the number of participants calculated by a standard sample size calculation for a single adequately powered equivalence study. As such, presenting only trends in the results, more studies are needed to provide robust evidence with regards to these trends. Thirdly, it is common for people with cervical dystonia to have concomitant medications for their condition, such as muscle relaxants and benzodiazepines. Reasonably, in trials, participants are required to be on a stable dose of these medications for many weeks to avoid confounding factors. As a result, little is known at present about the impact of these drug regimens with regard to implementation of the evidence in this review. Fourthly, several outcomes of interest were either poorly reported or entirely omitted. Specifically, no quality of life assessments were reported in any of the included studies; subjective assessments by both participants and clinicians were not reported in two of the included studies; the proportion of participants with adverse events was also not reported in two of the included studies; and the time to effect was not reported in any of the included trials, which is of interest as this is clinically relevant for both participants and clinicians, as well as a potentially important differentiating factor between BtA and BtB. </p> </section> <section id="CD004314-sec-0097"> <h3 class="title" id="CD004314-sec-0097">Quality of the evidence</h3> <p>See <a href="./references#CD004314-sec-0118" title="">Characteristics of included studies</a>, 'Risk of bias' tables, and 'Risk of bias' summary tables (<a href="#CD004314-fig-0002">Figure 2</a>; <a href="#CD004314-fig-0003">Figure 3</a>). </p> <p>We considered all studies to be at high risk of bias due to for‐profit bias. We additionally considered <a href="./references#CD004314-bbs2-0003" title="TintnerR , GrossR , WinzerUF , SmalkyKA , JankovicJ . Autonomic function after botulinum toxin type A or B: a double‐blind, randomized trial. Neurology2005;65:765‐7. ">Tintner 2005</a> to be at a high risk of reporting bias, since it did not report outcomes that were collected, without providing any explanation for this omission. Additionally, we judged <a href="./references#CD004314-bbs2-0003" title="TintnerR , GrossR , WinzerUF , SmalkyKA , JankovicJ . Autonomic function after botulinum toxin type A or B: a double‐blind, randomized trial. Neurology2005;65:765‐7. ">Tintner 2005</a> to be at an unclear risk of bias for all 'Risk of bias' domains with the exception of attrition bias. We considered the risk of bias due to an enriched population to be high in <a href="./references#CD004314-bbs2-0001" title="ComellaCL , JankovicJ , ShannonKM , TsuiJ , SwensonM , LeurgansS , et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology2005;65:1423‐9. [DOI: 10.1212/01.wnl.0000183055.81056.5c] ">Comella 2005</a> and <a href="./references#CD004314-bbs2-0003" title="TintnerR , GrossR , WinzerUF , SmalkyKA , JankovicJ . Autonomic function after botulinum toxin type A or B: a double‐blind, randomized trial. Neurology2005;65:765‐7. ">Tintner 2005</a>, and unclear in <a href="./references#CD004314-bbs2-0002" title="PappertEJ , GermansonT . Botulinum toxin type B vs. type A in toxin‐naïve patients with cervical dystonia: randomized double‐blind, noninferiority trial. Movement Disorders2008;23:510‐7. ">Pappert 2008</a>. Finally, statistical heterogeneity was low for all outcomes with the exception of the proportion of participants with sore throat/dry mouth. </p> <p>Some outcomes could not be compared across studies, as some studies lacked reporting of relevant data. Imbalances between baseline characteristics of the participants and incomplete description of the variables prevented confident imputation of values for missing data, which further reduced the amount of combinable data, and therefore the precision of the results. </p> <p>The included trials enrolled between 20 and 139 participants, each individually enrolling fewer participants than the total number that would be required for a single adequately‐powered equivalence trial of BtA versus BtB. Collectively however, only the following outcomes were under‐powered: overall proportion of participants with adverse events, change in subjective evaluation of clinical status evaluated by patients, and changes in pain scores. </p> <p>Taken together, as can be seen in <a href="./full#CD004314-tbl-0001">summary of findings Table for the main comparison</a>, we consider that there is low quality evidence that a single treatment session of BtA and a single treatment session of BtB, in certain types of cervical dystonia, are equally efficacious in reducing disease impairment, including severity, disability, and pain. The quality of evidence supporting the higher occurrence of sore throat/dry mouth among BtB‐treated individuals is moderate. There is also low‐quality evidence that dysphagia occurs at the same rate in people treated with BtA and BtB. The quality of evidence assessing the change in subjective evaluation of clinical status evaluated by patients is low. Regarding the overall safety and tolerability comparison, the quality of the evidence is low, meaning that we are unable to draw any robust conclusions. Additionally, we can draw no conclusions regarding continued responsiveness and long‐term efficacy, which are important aspects to consider in a chronic condition such as cervical dystonia. </p> </section> <section id="CD004314-sec-0098"> <h3 class="title" id="CD004314-sec-0098">Potential biases in the review process</h3> <p>Although we followed the methods recommended by Cochrane in order to minimise bias in the review process, certain areas do deserve attention. Despite having contacted experts in the area extensively, not having searched all available clinical trial registries opens the current review to two potential problems: firstly, the possibility of having missed trials and also the possibility of introducing publication bias. We opted not to search trial registries as the trials that have been conducted are well‐known in the area, and this form of search was not included in the review protocol. </p> <p>An additional bias was that we could not obtain data for all outcomes in the included trials. A further limitation of this review is the small number of participants contributing data to each outcome. Therefore, the results of the pooled analysis should be viewed with caution, especially in the presence of statistical heterogeneity, as further studies may have an important impact in effect size estimations. </p> </section> <section id="CD004314-sec-0099"> <h3 class="title" id="CD004314-sec-0099">Agreements and disagreements with other studies or reviews</h3> <p>The current review is, to our knowledge, the first systematic review with data that address the question of whether one type of botulinum toxin is superior to another or not. We have included all randomised controlled trials that addressed this question in the current review. </p> <p><a href="./references#CD004314-bbs2-0001" title="ComellaCL , JankovicJ , ShannonKM , TsuiJ , SwensonM , LeurgansS , et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology2005;65:1423‐9. [DOI: 10.1212/01.wnl.0000183055.81056.5c] ">Comella 2005</a> reported a very large proportion of BtB‐treated participants with dysphagia and sore throat/dry mouth at week 4, particularly when compared to the available evidence from RCTs (dysphagia in <a href="./references#CD004314-bbs2-0001" title="ComellaCL , JankovicJ , ShannonKM , TsuiJ , SwensonM , LeurgansS , et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology2005;65:1423‐9. [DOI: 10.1212/01.wnl.0000183055.81056.5c] ">Comella 2005</a>: 80%; dysphagia in <a href="./references#CD004314-bbs2-0057" title="MarquesRE , DuarteGS , RodriguesFB , CastelãoM , FerreiraJ , SampaioC , et al. Botulinum toxin type B for cervical dystonia. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD004315.pub3; PUBMED: 27176573] ">Marques 2016</a>: 16%; sore throat/dry mouth in <a href="./references#CD004314-bbs2-0001" title="ComellaCL , JankovicJ , ShannonKM , TsuiJ , SwensonM , LeurgansS , et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology2005;65:1423‐9. [DOI: 10.1212/01.wnl.0000183055.81056.5c] ">Comella 2005</a>: 48%; sore throat/dry mouth in <a href="./references#CD004314-bbs2-0057" title="MarquesRE , DuarteGS , RodriguesFB , CastelãoM , FerreiraJ , SampaioC , et al. Botulinum toxin type B for cervical dystonia. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD004315.pub3; PUBMED: 27176573] ">Marques 2016</a>: 17%). However, the participants with these adverse events at baseline was likewise very high (baseline dysphagia in <a href="./references#CD004314-bbs2-0001" title="ComellaCL , JankovicJ , ShannonKM , TsuiJ , SwensonM , LeurgansS , et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology2005;65:1423‐9. [DOI: 10.1212/01.wnl.0000183055.81056.5c] ">Comella 2005</a>: 14%; baseline sore throat/dry mouth in <a href="./references#CD004314-bbs2-0001" title="ComellaCL , JankovicJ , ShannonKM , TsuiJ , SwensonM , LeurgansS , et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology2005;65:1423‐9. [DOI: 10.1212/01.wnl.0000183055.81056.5c] ">Comella 2005</a>: 37%), as the study exclusively enrolled people already being treated with BtA for cervical dystonia. For this reason, we opted to study the proportion of newly‐developed cases of each adverse event in comparison to baseline, with the results being more in‐line with both the available evidence and clinical practice (See <a href="#CD004314-tbl-0003">Table 2</a> for a comparison of dysphagia and sore throat/dry mouth in <a href="./references#CD004314-bbs2-0001" title="ComellaCL , JankovicJ , ShannonKM , TsuiJ , SwensonM , LeurgansS , et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology2005;65:1423‐9. [DOI: 10.1212/01.wnl.0000183055.81056.5c] ">Comella 2005</a>, <a href="./references#CD004314-bbs2-0057" title="MarquesRE , DuarteGS , RodriguesFB , CastelãoM , FerreiraJ , SampaioC , et al. Botulinum toxin type B for cervical dystonia. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD004315.pub3; PUBMED: 27176573] ">Marques 2016</a>, and the current review). </p> <div class="table" id="CD004314-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Percentage of BtB‐treated participants with adverse events of special interest: Comella 2005 versus Marques 2016 versus current review</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse event of special interest</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004314-bbs2-0001" title="ComellaCL , JankovicJ , ShannonKM , TsuiJ , SwensonM , LeurgansS , et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology2005;65:1423‐9. [DOI: 10.1212/01.wnl.0000183055.81056.5c] "><b>Comella 2005</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004314-bbs2-0057" title="MarquesRE , DuarteGS , RodriguesFB , CastelãoM , FerreiraJ , SampaioC , et al. Botulinum toxin type B for cervical dystonia. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD004315.pub3; PUBMED: 27176573] ">Marques 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Current review</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sore throat/dry mouth</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Dysphagia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29%</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><a href="./references#CD004314-bbs2-0057" title="MarquesRE , DuarteGS , RodriguesFB , CastelãoM , FerreiraJ , SampaioC , et al. Botulinum toxin type B for cervical dystonia. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD004315.pub3; PUBMED: 27176573] ">Marques 2016</a> is a Cochrane systematic review that studied efficacy and safety of BtB compared to placebo </p> </div> </div> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD004314-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/urn:x-wiley:14651858:media:CD004314:CD004314-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/image_t/tCD004314-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="BtA vs BtB in Cervical Dystonia Flow Diagram." data-id="CD004314-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/image_n/nCD004314-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>BtA vs BtB in Cervical Dystonia Flow Diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/full#CD004314-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/image_n/nCD004314-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004314-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/urn:x-wiley:14651858:media:CD004314:CD004314-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/image_t/tCD004314-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD004314-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/image_n/nCD004314-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/full#CD004314-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/image_n/nCD004314-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004314-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/urn:x-wiley:14651858:media:CD004314:CD004314-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/image_t/tCD004314-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD004314-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/image_n/nCD004314-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/full#CD004314-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/image_n/nCD004314-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004314-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/urn:x-wiley:14651858:media:CD004314:CD004314-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/image_t/tCD004314-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Botulinum toxin type A versus botulinum toxin type B, outcome: 1.1 Overall cervical dystonia improvement as assessed with validated scales: change from baseline to week 4." data-id="CD004314-fig-0004" src="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/image_n/nCD004314-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Botulinum toxin type A versus botulinum toxin type B, outcome: 1.1 Overall cervical dystonia improvement as assessed with validated scales: change from baseline to week 4. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/full#CD004314-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/image_n/nCD004314-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004314-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/urn:x-wiley:14651858:media:CD004314:CD004314-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/image_t/tCD004314-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Botulinum toxin type A versus botulinum toxin type B, Outcome 1 Overall cervical dystonia improvement as assessed with validated scales: change from baseline to week 4." data-id="CD004314-fig-0005" src="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/image_n/nCD004314-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Botulinum toxin type A versus botulinum toxin type B, Outcome 1 Overall cervical dystonia improvement as assessed with validated scales: change from baseline to week 4. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/references#CD004314-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/image_n/nCD004314-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004314-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/urn:x-wiley:14651858:media:CD004314:CD004314-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/image_t/tCD004314-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Botulinum toxin type A versus botulinum toxin type B, Outcome 2 Cervical dystonia associated severity: change from baseline to week 2‐4 as assessed with validated scales." data-id="CD004314-fig-0006" src="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/image_n/nCD004314-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Botulinum toxin type A versus botulinum toxin type B, Outcome 2 Cervical dystonia associated severity: change from baseline to week 2‐4 as assessed with validated scales. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/references#CD004314-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/image_n/nCD004314-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004314-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/urn:x-wiley:14651858:media:CD004314:CD004314-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/image_t/tCD004314-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Botulinum toxin type A versus botulinum toxin type B, Outcome 3 Cervical dystonia associated disability: change from baseline to week 2‐4 as assessed with validated scales." data-id="CD004314-fig-0007" src="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/image_n/nCD004314-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Botulinum toxin type A versus botulinum toxin type B, Outcome 3 Cervical dystonia associated disability: change from baseline to week 2‐4 as assessed with validated scales. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/references#CD004314-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/image_n/nCD004314-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004314-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/urn:x-wiley:14651858:media:CD004314:CD004314-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/image_t/tCD004314-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Botulinum toxin type A versus botulinum toxin type B, Outcome 4 Proportion of participants with adverse events." data-id="CD004314-fig-0008" src="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/image_n/nCD004314-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Botulinum toxin type A versus botulinum toxin type B, Outcome 4 Proportion of participants with adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/references#CD004314-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/image_n/nCD004314-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004314-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/urn:x-wiley:14651858:media:CD004314:CD004314-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/image_t/tCD004314-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Botulinum toxin type A versus botulinum toxin type B, Outcome 5 Subjective change as assessed by the patient at week 4." data-id="CD004314-fig-0009" src="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/image_n/nCD004314-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Botulinum toxin type A versus botulinum toxin type B, Outcome 5 Subjective change as assessed by the patient at week 4. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/references#CD004314-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/image_n/nCD004314-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004314-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/urn:x-wiley:14651858:media:CD004314:CD004314-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/image_t/tCD004314-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Botulinum toxin type A versus botulinum toxin type B, Outcome 6 Subjective change as assessed by clinician at week 4." data-id="CD004314-fig-0010" src="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/image_n/nCD004314-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Botulinum toxin type A versus botulinum toxin type B, Outcome 6 Subjective change as assessed by clinician at week 4. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/references#CD004314-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/image_n/nCD004314-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004314-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/urn:x-wiley:14651858:media:CD004314:CD004314-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/image_t/tCD004314-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Botulinum toxin type A versus botulinum toxin type B, Outcome 7 Cervical dystonia associated pain: change from baseline to week 2‐4 as assessed with validated scales." data-id="CD004314-fig-0011" src="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/image_n/nCD004314-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Botulinum toxin type A versus botulinum toxin type B, Outcome 7 Cervical dystonia associated pain: change from baseline to week 2‐4 as assessed with validated scales. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/references#CD004314-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/image_n/nCD004314-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004314-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/urn:x-wiley:14651858:media:CD004314:CD004314-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/image_t/tCD004314-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Botulinum toxin type A versus botulinum toxin type B, Outcome 8 Adverse event: sore throat/dry mouth." data-id="CD004314-fig-0012" src="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/image_n/nCD004314-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Botulinum toxin type A versus botulinum toxin type B, Outcome 8 Adverse event: sore throat/dry mouth. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/references#CD004314-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/image_n/nCD004314-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004314-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/urn:x-wiley:14651858:media:CD004314:CD004314-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/image_t/tCD004314-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Botulinum toxin type A versus botulinum toxin type B, Outcome 9 Adverse event: dysphagia." data-id="CD004314-fig-0013" src="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/image_n/nCD004314-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Botulinum toxin type A versus botulinum toxin type B, Outcome 9 Adverse event: dysphagia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/references#CD004314-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/image_n/nCD004314-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004314-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/urn:x-wiley:14651858:media:CD004314:CD004314-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/image_t/tCD004314-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Botulinum toxin type A versus botulinum toxin type B, Outcome 10 Adverse event: injection site pain." data-id="CD004314-fig-0014" src="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/image_n/nCD004314-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Botulinum toxin type A versus botulinum toxin type B, Outcome 10 Adverse event: injection site pain. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/references#CD004314-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/media/CDSR/CD004314/image_n/nCD004314-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD004314-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Botulinum toxin type A versus botulinum toxin type B for adults with cervical dystonia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Botulinum toxin type A compared to botulinum toxin type B for adults with cervical dystonia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with cervical dystonia<br/> <b>Settings:</b> hospital‐based, movement disorders clinics<br/> <b>Intervention:</b> botulinum toxin type A<br/> <b>Comparison:</b> botulinum toxin type B </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>What happens</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>With botulinum toxin type A</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>With botulinum toxin type B</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Difference</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall cervical dystonia improvement:</b> change from baseline to week 4 assessed with TWSTRS total score<br/> Scale (range, 0 to 85; more is worst)<br/> № of participants: 231<br/> (2 RCTs) </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9.1 TWSTRS units decrease</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.5 TWSTRS units decrease</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline was 1.44 TWSTRS units higher (0.7 lower to 3.58 higher) in the BtB group compared to the BtA group </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>LOW <sup>1, 2</sup> </b> </p> <p>Due to study limitations and imprecision</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There may be little or no difference in the overall cervical dystonia improvement</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants with adverse events</b> <br/> № of participants: 111<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.40</b> <br/> (1.00 to 1.96) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>47.3%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66.2%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.9% more adverse events<br/> (0 fewer to 45.4 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>LOW <sup>3</sup> </b> </p> <p>Due to imprecision</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There may be little or no difference in the risk of adverse events</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Subjective change as assessed by the patient at week 4</b> </p> <p>assessed with: PGA<br/> Scale (range, ‐4 to 4; more is worst)<br/> № of participants: 138<br/> (1 RCT) </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1.6 PGA units decrease</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4 PGA units decrease</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean subjective change in the BtB group was 0.2 PGA units lower (0.17 lower to 0.57 higher) compared to the BtA group </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>LOW <sup>2, 4</sup> </b> </p> <p>Due to study limitations and imprecision</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There may be little or no difference in subjective assessment</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cervical dystonia associated pain: change from baseline to week 2‐4</b> <br/> assessed with TWSTRS pain sub‐scale<br/> Scale (range, 0 to 20; more is worst)<br/> № of participants: 251<br/> (3 RCTs) </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2.63 TWSTRS units decrease</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.45 TWSTRS units decrease</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean change was 0.83 TWSTRS units higher (1.75 lower to 0.09 higher) in the BtB group compared to the BtA group </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>LOW <sup>2, 4</sup> </b> </p> <p>Due to study limitations and imprecision</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There may be little or no difference in the risk of cervical dystonia‐associated pain</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events: sore throat/dry mouth</b> <br/> № of participants: 212<br/> (2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>RR 4.39</b> <br/> (2.43 to 7.91) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10.5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46.7%</p> <p>(25.5 to 82.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35.5% more</p> <p>(15 more to 72.4 more)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>MODERATE<sup>2, 4</sup> </b> </p> <p>Due to study limitations and imprecision</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BtB treatment probably increases the risk of sore throat/dry mouth</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events: dysphagia</b> <br/> № of participants: 249<br/> (3 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.89</b> <br/> (0.80 to 10.41) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10.2%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.4%</p> <p>(8.1 to 100.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.2% more</p> <p>(2 fewer to 95.6 more)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>LOW <sup>2, 4, 5</sup> </b> </p> <p>Due to study limitations, imprecision, and inconsistency</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There may be little or no difference in the risk of dysphagia</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>BtA:</b> botulinum toxin type A; <b>BtB:</b> botulinum toxin type B; <b>CI:</b> confidence interval;<b>PGA:</b> Patient Global Assessment; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>TWSTRS:</b> Toronto Western Spasmodic Torticollis Rating Scale </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Serious imprecision: 95% CI includes both appreciable benefit and no effect. This means that we cannot conclusively state the equivalence of these two formulations. </p> <p><sup>2</sup> Serious study limitations: the limitations in the studies assessing this outcome are serious and affect our confidence in the accuracy of the effect estimate. </p> <p><sup>3</sup> Very serious imprecision: the total number of participants included was less than the number generated by a conventional sample size calculation for a single adequately powered equivalence trial. 95% CI includes both appreciable benefit and harm meaning that we cannot conclusively state the equivalence of these two formulations. </p> <p><sup>4</sup> Serious imprecision: the total number of participants included was less than the number generated by a conventional sample size calculation for a single adequately powered equivalence trial. </p> <p><sup>5</sup> Serious inconsistency: high degree of heterogeneity expressed by I<sup>2</sup> and low overlap of 95% CI. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Botulinum toxin type A versus botulinum toxin type B for adults with cervical dystonia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/full#CD004314-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004314-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary of terms</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Term</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Definition</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> BtA‐non‐responsive</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>People who do not experience the expected benefit from treatment with botulinum toxin type A </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Cervical dystonia or spasmodic torticollis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A common movement disorder in which people have abnormal movements or postures of the head and neck that they cannot control. It is frequently accompanied by social embarrassment and pain. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Chemodenervation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The process by which botulinum toxin causes muscular paralysis. Although all the anatomical elements necessary for muscular control are intact (i.e. nerve, synapse and muscle), there is a chemical process that disables the transmission of the electrical signal from the nerve to the muscle. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Dysphagia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Discomfort or difficulty when swallowing</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Electromyography</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>An examination that displays the electrical activity of muscles using pieces of metal attached to the skin or inserted into the muscle </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Non‐naive</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>People who have been treated in the past with botulinum toxin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Voluntary action</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Movements that are normally under a person's control, that can be started and stopped at will </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary of terms</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/full#CD004314-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004314-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Percentage of BtB‐treated participants with adverse events of special interest: Comella 2005 versus Marques 2016 versus current review</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse event of special interest</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004314-bbs2-0001" title="ComellaCL , JankovicJ , ShannonKM , TsuiJ , SwensonM , LeurgansS , et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology2005;65:1423‐9. [DOI: 10.1212/01.wnl.0000183055.81056.5c] "><b>Comella 2005</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004314-bbs2-0057" title="MarquesRE , DuarteGS , RodriguesFB , CastelãoM , FerreiraJ , SampaioC , et al. Botulinum toxin type B for cervical dystonia. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD004315.pub3; PUBMED: 27176573] ">Marques 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Current review</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sore throat/dry mouth</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Dysphagia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29%</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p><a href="./references#CD004314-bbs2-0057" title="MarquesRE , DuarteGS , RodriguesFB , CastelãoM , FerreiraJ , SampaioC , et al. Botulinum toxin type B for cervical dystonia. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD004315.pub3; PUBMED: 27176573] ">Marques 2016</a> is a Cochrane systematic review that studied efficacy and safety of BtB compared to placebo </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Percentage of BtB‐treated participants with adverse events of special interest: Comella 2005 versus Marques 2016 versus current review</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/full#CD004314-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004314-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Botulinum toxin type A versus botulinum toxin type B</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall cervical dystonia improvement as assessed with validated scales: change from baseline to week 4 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.44 [‐3.58, 0.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Cervical dystonia associated severity: change from baseline to week 2‐4 as assessed with validated scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>251</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.26 [‐1.27, 0.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Cervical dystonia associated disability: change from baseline to week 2‐4 as assessed with validated scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>251</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.17 [‐1.19, 0.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Proportion of participants with adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [1.00, 1.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Subjective change as assessed by the patient at week 4 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐0.17, 0.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Subjective change as assessed by clinician at week 4 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐0.20, 0.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Cervical dystonia associated pain: change from baseline to week 2‐4 as assessed with validated scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>251</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.83 [‐1.75, 0.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Adverse event: sore throat/dry mouth <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.39 [2.43, 7.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Adverse event: dysphagia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.89 [0.80, 10.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Adverse event: injection site pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.01, 2.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Botulinum toxin type A versus botulinum toxin type B</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004314.pub3/references#CD004314-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD004314.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD004314-note-0008">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD004314-note-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD004314-note-0007">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD004314-note-0013">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD004314-note-0006">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD004314-note-0005">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004314\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004314\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004314\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004314\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004314\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004314\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004314\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004314\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004314\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004314\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004314\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004314\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004314\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004314\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004314\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004314\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004314\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004314\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=zCmos3jT&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004314.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004314.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD004314.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD004314.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004314.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725537832"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004314.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725537836"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004314.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e7da18fb6f4b8',t:'MTc0MDcyNTUzOC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 